



US00888702B2

(12) **United States Patent**
Osorio

(10) **Patent No.:** **US 8,888,702 B2**
(45) **Date of Patent:** **Nov. 18, 2014**

(54) **DETECTING, QUANTIFYING, AND/OR CLASSIFYING SEIZURES USING MULTIMODAL DATA**

(71) Applicant: **Flint Hills Scientific, LLC**, Lawrence, KS (US)

(72) Inventor: **Ivan Osorio**, Leawood, KS (US)

(73) Assignee: **Flint Hills Scientific, LLC**, Lawrence, KS (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 51 days.

(21) Appl. No.: **13/692,738**

(22) Filed: **Dec. 3, 2012**

(65) **Prior Publication Data**

US 2013/0096441 A1 Apr. 18, 2013

Related U.S. Application Data

(63) Continuation of application No. 12/896,525, filed on Oct. 1, 2010, now Pat. No. 8,337,404.

(51) **Int. Cl.**

A61B 5/00 (2006.01)

A61B 5/0245 (2006.01)

A61B 5/11 (2006.01)

A61B 5/0205 (2006.01)

A61B 5/0476 (2006.01)

A61N 1/36 (2006.01)

A61N 1/365 (2006.01)

A61B 5/145 (2006.01)

(52) **U.S. Cl.**

CPC **A61B 5/0205** (2013.01); **A61B 5/0245** (2013.01); **A61N 1/36064** (2013.01); **A61B 5/11** (2013.01); **A61B 5/7282** (2013.01); **A61N 1/36585** (2013.01); **A61B 5/0476** (2013.01); **A61B 5/7264** (2013.01); **A61N 1/36135** (2013.01); **A61B 5/14539** (2013.01); **A61B 5/686** (2013.01); **A61B 5/02055** (2013.01); **A61B 5/14542** (2013.01); **A61B 5/4094** (2013.01)

USPC **600/301**

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,172,459 A	10/1979	Hepp
4,197,856 A	4/1980	Northrop
4,291,699 A	9/1981	Geddes et al.
4,320,766 A	3/1982	Alihanka et al.
4,541,432 A	9/1985	Molina-Negro et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	1145736	10/2001
EP	1486232	12/2004

(Continued)

OTHER PUBLICATIONS

Bachman, D., S. et al.; "Effects of Vagal Volleys and Serotonin on Units of Cingulate Cortex in Monkeys;" Brain Research, vol. 130 (1977). pp. 253-269.

Baevskii, R.M. "Analysis of Heart Rate Variability in Space Medicine;" Human Physiology, vol. 28, No. 2, (2002); pp. 202-213.

Baevsky, R.M., et al.; "Autonomic Cardiovascular and Respiratory Control During Prolonged Spaceflights Aboard the International Space Station;" J. Applied Physiological, vol. 103, (2007) pp. 156-161.

Boon, P., et al.; "Vagus Nerve Stimulation for Epilepsy, Clinical Efficacy of Programmed and Magnet Stimulation;" (2001); pp. 93-98.

Boon, Paul, et al.; "Programmed and Magnet-Induced Vagus Nerve Stimulation for Refractory Epilepsy;" Journal of Clinical Neurophysiology vol. 18 No. 5; (2001); pp. 402-407.

(Continued)


Primary Examiner — Brian T Gedeon

(57)

ABSTRACT

Methods, systems, and apparatus for detecting an epileptic event, for example, a seizure in a patient using a medical device. The determination is performed by providing an autonomic signal indicative of the patient's autonomic activity; providing a neurologic signal indicative of the patient's neurological activity; and detecting an epileptic event based upon the autonomic signal and the neurologic signal.

21 Claims, 11 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

4,573,481	A	3/1986	Bullara	5,978,972	A	11/1999	Stewart et al.
4,702,254	A	10/1987	Zabara	5,987,352	A	11/1999	Klein et al.
4,867,164	A	9/1989	Zabara	5,995,868	A	11/1999	Osorio et al.
4,920,979	A	5/1990	Bullara	6,016,449	A	1/2000	Fischell et al.
4,949,721	A	8/1990	Toriu et al.	6,018,682	A	1/2000	Rise
4,979,511	A	12/1990	Terry, Jr.	6,048,324	A	4/2000	Socci et al.
5,025,807	A	6/1991	Zabara	6,061,593	A	5/2000	Fischell et al.
5,062,169	A	11/1991	Kennedy et al.	6,073,048	A	6/2000	Kieval et al.
5,113,869	A	5/1992	Nappholz et al.	6,083,249	A	7/2000	Familoni
5,137,020	A	8/1992	Wayne et al.	6,091,992	A	7/2000	Bourgeois et al.
5,154,172	A	10/1992	Terry, Jr. et al.	6,095,991	A	8/2000	Krausman et al.
5,179,950	A	1/1993	Stanislaw	6,104,956	A	8/2000	Naritoku et al.
5,186,170	A	2/1993	Varrichio et al.	6,115,628	A	9/2000	Stadler et al.
5,188,104	A	2/1993	Wernicke et al.	6,115,630	A	9/2000	Stadler et al.
5,194,847	A	3/1993	Taylor et al.	6,128,538	A	10/2000	Fischell et al.
5,203,326	A	4/1993	Collins	6,134,474	A	10/2000	Fischell et al.
5,205,285	A	4/1993	Baker, Jr.	6,162,191	A	12/2000	Foxlin
5,213,568	A	5/1993	Lattin et al.	6,163,281	A	12/2000	Torch
5,215,086	A	6/1993	Terry, Jr. et al.	6,167,311	A	12/2000	Rezai
5,215,089	A	6/1993	Baker, Jr.	6,171,239	B1	1/2001	Humphrey
5,222,494	A	6/1993	Baker, Jr.	6,175,764	B1	1/2001	Loeb et al.
5,231,988	A	8/1993	Wernicke et al.	6,205,359	B1	3/2001	Boveja
5,235,980	A	8/1993	Varrichio et al.	6,208,894	B1	3/2001	Schulman et al.
5,237,991	A	8/1993	Baker, Jr. et al.	6,208,902	B1	3/2001	Boveja
5,243,980	A	9/1993	Mehra	6,221,908	B1	4/2001	Kilgard et al.
5,251,634	A	10/1993	Weinberg	6,246,344	B1	6/2001	Torch
5,263,480	A	11/1993	Wernicke et al.	6,248,080	B1	6/2001	Miesel et al.
5,269,302	A	12/1993	Swartz et al.	6,253,109	B1	6/2001	Gielen
5,269,303	A	12/1993	Wernicke et al.	6,269,270	B1	7/2001	Boveja
5,299,569	A	4/1994	Wernicke et al.	6,272,379	B1	8/2001	Fischell et al.
5,304,206	A	4/1994	Baker, Jr. et al.	6,304,775	B1	10/2001	Iasemidis et al.
5,311,876	A	5/1994	Olsen et al.	6,315,740	B1	11/2001	Singh
5,313,953	A	5/1994	Yomtov et al.	6,324,421	B1	11/2001	Stadler et al.
5,330,507	A	7/1994	Schwartz	6,337,997	B1	1/2002	Rise
5,330,515	A	7/1994	Rutecki et al.	6,339,725	B1	1/2002	Naritoku et al.
5,334,221	A	8/1994	Bardy	6,341,236	B1	1/2002	Osorio et al.
5,335,657	A	8/1994	Terry, Jr. et al.	6,356,784	B1	3/2002	Lozano et al.
5,404,877	A	4/1995	Nolan et al.	6,356,788	B2	3/2002	Boveja
5,425,373	A	6/1995	Causey, III	6,361,507	B1	3/2002	Foxlin
5,513,649	A	5/1996	Gevens et al.	6,361,508	B1	3/2002	Johnson et al.
5,522,862	A	6/1996	Testerman et al.	6,366,813	B1	4/2002	DiLorenzo
5,523,742	A	6/1996	Simkins et al.	6,366,814	B1	4/2002	Boveja
5,540,730	A	7/1996	Terry, Jr. et al.	6,374,140	B1	4/2002	Rise
5,540,734	A	7/1996	Zabara	6,397,100	B2	5/2002	Stadler et al.
5,571,150	A	11/1996	Wernicke et al.	6,427,086	B1	7/2002	Fischell et al.
5,610,590	A	3/1997	Johnson et al.	6,429,217	B1	8/2002	Puskas
5,611,350	A	3/1997	John	6,441,731	B1	8/2002	Hess
5,645,077	A	7/1997	Foxlin	6,449,512	B1	9/2002	Boveja
5,645,570	A	7/1997	Corbucci	6,459,936	B2	10/2002	Fischell et al.
5,651,378	A	7/1997	Matheny et al.	6,463,328	B1	10/2002	John
5,658,318	A	8/1997	Stroetmann et al.	6,466,822	B1	10/2002	Pless
5,683,422	A	11/1997	Rise et al.	6,473,639	B1	10/2002	Fischell et al.
5,690,681	A	11/1997	Geddes et al.	6,473,644	B1	10/2002	Terry, Jr. et al.
5,690,688	A	11/1997	Noren et al.	6,477,418	B2	11/2002	Plicchi et al.
5,700,282	A	12/1997	Zabara	6,480,743	B1	11/2002	Kirkpatrick et al.
5,707,400	A	1/1998	Terry, Jr. et al.	6,484,132	B1	11/2002	Hively et al.
5,716,377	A	2/1998	Rise et al.	6,501,983	B1	12/2002	Natarajan et al.
5,720,771	A	2/1998	Snell	6,505,074	B2	1/2003	Boveja et al.
5,743,860	A	4/1998	Hively et al.	6,532,388	B1	3/2003	Hill et al.
5,748,113	A	5/1998	Torch	6,539,263	B1	3/2003	Schiff et al.
5,792,186	A	8/1998	Rise	6,542,081	B2	4/2003	Torch
5,800,474	A	9/1998	Benabid et al.	6,542,774	B2	4/2003	Hill et al.
5,807,284	A	9/1998	Foxlin	6,549,804	B1	4/2003	Osorio et al.
5,808,552	A	9/1998	Wiley et al.	6,556,868	B2	4/2003	Naritoku et al.
5,833,709	A	11/1998	Rise et al.	6,560,486	B1	5/2003	Osorio et al.
5,853,005	A	12/1998	Scanlon et al.	6,564,102	B1	5/2003	Boveja
5,879,309	A	3/1999	Johnson et al.	6,587,719	B1	7/2003	Barrett et al.
5,905,436	A	5/1999	Dwight et al.	6,587,727	B2	7/2003	Osorio et al.
5,913,876	A	6/1999	Taylor et al.	6,594,524	B2	7/2003	Esteller et al.
5,916,181	A	6/1999	Socci et al.	6,599,250	B2	7/2003	Webb et al.
5,916,239	A	6/1999	Geddes et al.	6,609,025	B2	8/2003	Barrett et al.
5,928,272	A	7/1999	Adkins et al.	6,610,713	B2	8/2003	Tracey
5,941,906	A	8/1999	Barreras, Sr. et al.	6,611,715	B1	8/2003	Boveja
5,942,979	A	8/1999	Luppino	6,611,783	B2	8/2003	Kelly, Jr. et al.
5,978,702	A	11/1999	Ward et al.	6,615,081	B1	9/2003	Boveja
				6,615,085	B1	9/2003	Boveja
				6,622,038	B2	9/2003	Barrett et al.
				6,622,041	B2	9/2003	Terry, Jr. et al.
				6,622,047	B2	9/2003	Barrett et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,628,985	B2	9/2003	Sweeney et al.	7,242,983	B2	7/2007	Frei et al.
6,628,987	B1	9/2003	Hill et al.	7,242,984	B2	7/2007	DiLorenzo
6,629,990	B2	10/2003	Putz et al.	7,254,439	B2	8/2007	Misczynski et al.
6,647,296	B2	11/2003	Fischell et al.	7,263,467	B2	8/2007	Sackellares et al.
6,656,125	B2	12/2003	Misczynski et al.	7,274,298	B2	9/2007	Frank
6,656,960	B2	12/2003	Puskas	7,277,758	B2	10/2007	DiLorenzo
6,668,191	B1	12/2003	Boveja	7,280,867	B2	10/2007	Frei et al.
6,671,555	B2	12/2003	Gielen et al.	7,282,030	B2	10/2007	Frei et al.
6,671,556	B2	12/2003	Osorio et al.	7,289,844	B2	10/2007	Misczynski et al.
6,684,105	B2	1/2004	Cohen et al.	7,292,890	B2	11/2007	Whitehurst et al.
6,721,603	B2	4/2004	Zabara et al.	7,295,881	B2	11/2007	Cohen et al.
6,730,047	B2	5/2004	Socci et al.	7,299,096	B2	11/2007	Balzer et al.
6,735,474	B1	5/2004	Loeb et al.	7,302,298	B2	11/2007	Lowry et al.
6,738,671	B2	5/2004	Christophersom et al.	7,304,580	B2	12/2007	Sullivan et al.
6,760,626	B1	7/2004	Boveja	7,305,268	B2	12/2007	Gliner et al.
6,763,256	B2	7/2004	Kimball et al.	7,313,440	B2	12/2007	Miesel
6,768,969	B1	7/2004	Nikitin et al.	7,314,451	B2	1/2008	Halperin et al.
6,786,877	B2	9/2004	Foxlin	7,321,837	B2	1/2008	Osorio et al.
6,788,975	B1	9/2004	Whitehurst et al.	7,324,850	B2	1/2008	Persen et al.
6,793,670	B2	9/2004	Osorio et al.	7,324,851	B1	1/2008	DiLorenzo
6,819,953	B2	11/2004	Yonce et al.	7,330,760	B2	2/2008	Heruth et al.
6,819,956	B2	11/2004	DiLorenzo	7,346,391	B1	3/2008	Osorio et al.
6,832,114	B1	12/2004	Whitehurst et al.	7,353,063	B2	4/2008	Simms, Jr.
6,836,685	B1	12/2004	Fitz	7,353,064	B2	4/2008	Gliner et al.
6,850,601	B2	2/2005	Jones et al.	7,373,199	B2	5/2008	Sackellares et al.
6,879,850	B2	4/2005	Kimball	7,385,443	B1	6/2008	Denison
6,885,888	B2	4/2005	Rezai	7,389,144	B1	6/2008	Osorio et al.
6,904,390	B2	6/2005	Nikitin et al.	7,389,147	B2	6/2008	Wahlstrand et al.
6,920,357	B2	7/2005	Osorio et al.	7,395,113	B2	7/2008	Heruth et al.
6,923,784	B2	8/2005	Stein	7,401,008	B2	7/2008	Frei et al.
6,931,274	B2	8/2005	Williams et al.	7,403,820	B2	7/2008	DiLorenzo
6,934,580	B1	8/2005	Osorio et al.	7,420,472	B2	9/2008	Tran
6,934,585	B1	8/2005	Schloss	7,433,732	B1	10/2008	Carney et al.
6,944,501	B1	9/2005	Pless	7,447,545	B2	11/2008	Heruth et al.
6,957,107	B2	10/2005	Rogers	7,454,245	B2	11/2008	Armstrong et al.
6,961,618	B2	11/2005	Osorio et al.	7,488,293	B2	2/2009	Marcovecchio et al.
6,984,993	B2	1/2006	Ariav	7,488,294	B2	2/2009	Torch
6,985,771	B2	1/2006	Fischell et al.	7,491,181	B2	2/2009	Heruth et al.
6,990,377	B2	1/2006	Gliner et al.	7,494,464	B2	2/2009	Rzesnitzeck et al.
7,006,859	B1	2/2006	Osorio et al.	7,502,643	B2	3/2009	Farringdon et al.
7,006,872	B2	2/2006	Gielen et al.	7,515,054	B2	4/2009	Torch
7,010,351	B2	3/2006	Firlik et al.	7,539,532	B2	5/2009	Tran
7,024,247	B2	4/2006	Gliner et al.	7,539,533	B2	5/2009	Tran
7,035,684	B2	4/2006	Lee	7,539,543	B2	5/2009	Schiff et al.
7,054,792	B2	5/2006	Frei et al.	7,558,622	B2	7/2009	Tran
7,058,453	B2	6/2006	Nelson et al.	7,565,132	B2	7/2009	Ben
7,068,842	B2	6/2006	Liang et al.	7,590,453	B2	9/2009	Heruth et al.
7,076,288	B2	7/2006	Skinner	7,620,456	B2	11/2009	Gliner et al.
7,077,810	B2	7/2006	Lange et al.	7,629,890	B2	12/2009	Sullivan et al.
7,079,977	B2	7/2006	Osorio et al.	7,643,655	B2	1/2010	Liang et al.
7,104,947	B2	9/2006	Riehl et al.	7,647,121	B2	1/2010	Wahlstrand et al.
7,110,820	B2	9/2006	Tcheng et al.	7,658,112	B2	2/2010	Nakamura
7,112,319	B2	9/2006	Broderick et al.	7,666,151	B2	2/2010	Sullivan et al.
7,127,370	B2	10/2006	Kelly et al.	7,714,757	B2	5/2010	Denison et al.
7,134,996	B2	11/2006	Bardy	7,717,848	B2	5/2010	Heruth et al.
7,139,677	B2	11/2006	Hively et al.	RE41,376	E	6/2010	Torch
7,146,211	B2	12/2006	Frei et al.	7,733,224	B2	6/2010	Tran
7,146,217	B2	12/2006	Firlik et al.	7,747,318	B2	6/2010	John et al.
7,146,218	B2	12/2006	Esteller et al.	7,769,464	B2	8/2010	Gerber et al.
7,149,572	B2	12/2006	Frei et al.	7,775,993	B2	8/2010	Heruth et al.
7,164,941	B2	1/2007	Misczynski et al.	7,792,583	B2	9/2010	Miesel et al.
7,167,743	B2	1/2007	Heruth et al.	7,801,603	B2	9/2010	Westlund et al.
7,167,750	B2	1/2007	Knudson et al.	7,801,618	B2	9/2010	Pless
7,174,206	B2	2/2007	Frei et al.	7,801,743	B2	9/2010	Graves et al.
7,177,678	B1	2/2007	Osorio et al.	7,813,802	B2	10/2010	Tcheng et al.
7,188,053	B2	3/2007	Nikitin et al.	7,822,481	B2	10/2010	Gerber et al.
RE39,539	E	4/2007	Torch	7,827,011	B2	11/2010	DeVaul et al.
7,204,833	B1	4/2007	Osorio et al.	7,831,305	B2	11/2010	Gliner
7,209,786	B2	4/2007	Brockway	7,847,628	B2	12/2010	Denison
7,209,787	B2	4/2007	DiLorenzo	7,866,212	B2	1/2011	Ariav et al.
7,221,981	B2	5/2007	Gliner	7,899,545	B2	3/2011	John
7,228,167	B2	6/2007	Kara	7,935,076	B2	5/2011	Estes et al.
7,231,254	B2	6/2007	DiLorenzo	RE42,471	E	6/2011	Torch
7,236,830	B2	6/2007	Gliner	7,957,809	B2	6/2011	Bourget et al.
7,236,831	B2	6/2007	Firlik et al.	7,965,833	B2	6/2011	Meir et al.
				7,974,671	B2	7/2011	Fujiwara et al.
				7,996,076	B2	8/2011	Burns et al.
				7,999,857	B2	8/2011	Bunn et al.
				8,000,789	B2	8/2011	Denison et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

8,000,794 B2	8/2011	Lozano	2005/0101873 A1	5/2005	Misczynski et al.
8,021,299 B2	9/2011	Miesel et al.	2005/0107716 A1	5/2005	Eaton et al.
8,027,730 B2	9/2011	John et al.	2005/0119703 A1	6/2005	DiLorenzo
8,027,737 B2	9/2011	Kokones et al.	2005/0124901 A1	6/2005	Misczynski et al.
8,075,499 B2	12/2011	Nathan et al.	2005/0131467 A1	6/2005	Boveja et al.
8,109,891 B2	2/2012	Kramer et al.	2005/0131485 A1	6/2005	Knudson et al.
2001/0032059 A1	10/2001	Kelly et al.	2005/0131486 A1	6/2005	Boveja et al.
2002/0072782 A1	6/2002	Osorio et al.	2005/0131493 A1	6/2005	Boveja et al.
2002/0099417 A1	7/2002	Naritoku et al.	2005/0143786 A1	6/2005	Boveja et al.
2002/0116030 A1	8/2002	Rezai	2005/0148893 A1	7/2005	Misczynski et al.
2002/0151939 A1	10/2002	Rezai	2005/0148894 A1	7/2005	Misczynski et al.
2002/0188214 A1	12/2002	Misczynski et al.	2005/0148895 A1	7/2005	Misczynski et al.
2003/0040680 A1	2/2003	Hassert et al.	2005/0153885 A1	7/2005	Yun et al.
2003/0074032 A1	4/2003	Gliner	2005/0154425 A1	7/2005	Boveja et al.
2003/0083716 A1	5/2003	Nicolelis et al.	2005/0154426 A1	7/2005	Boveja et al.
2003/0083726 A1	5/2003	Zeijlemaker et al.	2005/0165458 A1	7/2005	Boveja et al.
2003/0125786 A1	7/2003	Gliner et al.	2005/0187590 A1	8/2005	Boveja et al.
2003/0130706 A1	7/2003	Sheffield et al.	2005/0192644 A1	9/2005	Boveja et al.
2003/0144829 A1	7/2003	Geatz et al.	2005/0197590 A1	9/2005	Osorio et al.
2003/0181954 A1	9/2003	Rezai	2005/0203366 A1	9/2005	Donoghue et al.
2003/0181958 A1	9/2003	Dobak	2005/0245971 A1	11/2005	Brockway et al.
2003/0195588 A1	10/2003	Upton et al.	2005/0261542 A1	11/2005	Riehl
2003/0208212 A1	11/2003	Cigaina	2005/0277998 A1	12/2005	Tracey et al.
2003/0210147 A1	11/2003	Humbard	2005/0283200 A1	12/2005	Rezai et al.
2003/0212440 A1	11/2003	Boveja	2005/0283201 A1	12/2005	Machado et al.
2003/0236474 A1	12/2003	Singh	2005/0288600 A1	12/2005	Zhang et al.
2003/0236558 A1	12/2003	Whitehurst et al.	2005/0288760 A1	12/2005	Machado et al.
2004/0006278 A1	1/2004	Webb et al.	2006/0009815 A1	1/2006	Boveja
2004/0030365 A1	2/2004	Rubin et al.	2006/0018833 A1	1/2006	Murphy et al.
2004/0088024 A1	5/2004	Firlik et al.	2006/0074450 A1	4/2006	Boveja
2004/0111045 A1	6/2004	Sullivan et al.	2006/0079936 A1	4/2006	Boveja
2004/0122484 A1	6/2004	Hatlestad et al.	2006/0094971 A1	5/2006	Drew
2004/0122485 A1	6/2004	Stahmann et al.	2006/0095081 A1	5/2006	Zhou et al.
2004/0133119 A1	7/2004	Osorio et al.	2006/0106430 A1	5/2006	Fowler et al.
2004/0138516 A1	7/2004	Osorio et al.	2006/0135877 A1	6/2006	Giftakis et al.
2004/0138517 A1	7/2004	Osorio et al.	2006/0135881 A1	6/2006	Giftakis et al.
2004/0138647 A1	7/2004	Osorio et al.	2006/0149139 A1	7/2006	Bonmassar et al.
2004/0138711 A1	7/2004	Osorio et al.	2006/0155495 A1	7/2006	Osorio et al.
2004/0153129 A1	8/2004	Pless et al.	2006/0167497 A1	7/2006	Armstrong et al.
2004/0158119 A1	8/2004	Osorio et al.	2006/0173493 A1	8/2006	Armstrong et al.
2004/0158165 A1	8/2004	Yonce et al.	2006/0173522 A1	8/2006	Osorio
2004/0172085 A1	9/2004	Knudson et al.	2006/0190056 A1	8/2006	Fowler et al.
2004/0172091 A1	9/2004	Rezai	2006/0195163 A1	8/2006	KenKnight et al.
2004/0172094 A1	9/2004	Cohen et al.	2006/0200206 A1	9/2006	Firlik et al.
2004/0176812 A1	9/2004	Knudson et al.	2006/0212091 A1	9/2006	Lozano et al.
2004/0176831 A1	9/2004	Gliner et al.	2006/0212097 A1	9/2006	Varadan et al.
2004/0199212 A1	10/2004	Fischell et al.	2006/0224067 A1	10/2006	Giftakis et al.
2004/0225335 A1	11/2004	Whitehurst et al.	2006/0224191 A1	10/2006	DiLorenzo
2004/0249302 A1	12/2004	Donoghue et al.	2006/0241697 A1	10/2006	Libbus et al.
2004/0249416 A1	12/2004	Yun et al.	2006/0241725 A1	10/2006	Libbus et al.
2004/0267152 A1	12/2004	Pineda et al.	2006/0293720 A1	12/2006	DiLorenzo
2005/0004621 A1	1/2005	Boveja et al.	2007/0027486 A1	2/2007	Armstrong et al.
2005/0020887 A1	1/2005	Goldberg	2007/0027497 A1	2/2007	Parnis et al.
2005/0021092 A1	1/2005	Yun et al.	2007/0027498 A1	2/2007	Maschino et al.
2005/0021103 A1	1/2005	DiLorenzo	2007/0027500 A1	2/2007	Maschino et al.
2005/0021104 A1	1/2005	DiLorenzo	2007/0032834 A1	2/2007	Gliner et al.
2005/0021105 A1	1/2005	Firlik et al.	2007/0043392 A1	2/2007	Gliner et al.
2005/0021106 A1	1/2005	Firlik et al.	2007/0055320 A1	3/2007	Weinand et al.
2005/0021107 A1	1/2005	Firlik et al.	2007/0073150 A1	3/2007	Gopalsami et al.
2005/0021118 A1	1/2005	Genau et al.	2007/0073355 A1	3/2007	DiLorenzo
2005/0022606 A1	2/2005	Partin et al.	2007/0088403 A1	4/2007	Wylar et al.
2005/0027284 A1	2/2005	Lozano et al.	2007/0100278 A1	5/2007	Frei et al.
2005/0033378 A1	2/2005	Sheffield et al.	2007/0100392 A1	5/2007	Maschino et al.
2005/0033379 A1	2/2005	Lozano et al.	2007/0142862 A1	6/2007	DiLorenzo
2005/0038484 A1	2/2005	Knudson et al.	2007/0142873 A1	6/2007	Esteller et al.
2005/0049515 A1	3/2005	Misczynski et al.	2007/0150024 A1	6/2007	Leyde et al.
2005/0049655 A1	3/2005	Boveja et al.	2007/0150025 A1	6/2007	DiLorenzo et al.
2005/0060001 A1	3/2005	Singhal et al.	2007/0161919 A1	7/2007	DiLorenzo
2005/0065562 A1	3/2005	Rezai	2007/0162086 A1	7/2007	DiLorenzo
2005/0065573 A1	3/2005	Rezai	2007/0167991 A1	7/2007	DiLorenzo
2005/0065574 A1	3/2005	Rezai	2007/0173901 A1	7/2007	Reeve
2005/0065575 A1	3/2005	Dobak	2007/0173902 A1	7/2007	Maschino et al.
2005/0070971 A1	3/2005	Fowler et al.	2007/0179534 A1	8/2007	Firlik et al.
2005/0075701 A1	4/2005	Shafer	2007/0179557 A1	8/2007	Maschino et al.
2005/0075702 A1	4/2005	Shafer	2007/0179558 A1	8/2007	Gliner et al.
			2007/0208212 A1	9/2007	DiLorenzo
			2007/0213785 A1	9/2007	Osorio et al.
			2007/0233192 A1	10/2007	Craig
			2007/0239210 A1	10/2007	Libbus et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2007/0242661 A1 10/2007 Tran et al.
 2007/0244407 A1 10/2007 Osorio
 2007/0249953 A1 10/2007 Osorio et al.
 2007/0249954 A1 10/2007 Virag et al.
 2007/0255147 A1 11/2007 Drew et al.
 2007/0255155 A1 11/2007 Drew et al.
 2007/0260147 A1 11/2007 Giftakis et al.
 2007/0260289 A1 11/2007 Giftakis et al.
 2007/0265536 A1 11/2007 Giftakis et al.
 2007/0272260 A1 11/2007 Nikitin et al.
 2007/0282177 A1 12/2007 Pilz
 2008/0004904 A1 1/2008 Tran et al.
 2008/0033503 A1 2/2008 Fowler et al.
 2008/0033508 A1 2/2008 Frei et al.
 2008/0046035 A1 2/2008 Fowler et al.
 2008/0064934 A1 3/2008 Frei et al.
 2008/0071323 A1 3/2008 Lowry et al.
 2008/0077028 A1 3/2008 Schaldach et al.
 2008/0081958 A1 4/2008 Denison et al.
 2008/0103548 A1 5/2008 Fowler et al.
 2008/0114417 A1 5/2008 Leyde
 2008/0119900 A1 5/2008 DiLorenzo
 2008/0125820 A1 5/2008 Stahmann et al.
 2008/0139870 A1 6/2008 Gliner et al.
 2008/0146890 A1 6/2008 LeBoeuf et al.
 2008/0146959 A1 6/2008 Sheffield et al.
 2008/0161712 A1 7/2008 Leyde
 2008/0161713 A1 7/2008 Leyde et al.
 2008/0161879 A1 7/2008 Firlik et al.
 2008/0161880 A1 7/2008 Firlik et al.
 2008/0161881 A1 7/2008 Firlik et al.
 2008/0161882 A1 7/2008 Firlik et al.
 2008/0183096 A1 7/2008 Snyder et al.
 2008/0183097 A1 7/2008 Leyde et al.
 2008/0208013 A1 8/2008 Zhang et al.
 2008/0208284 A1 8/2008 Rezai et al.
 2008/0258907 A1 10/2008 Kalpaxis et al.
 2008/0269579 A1 10/2008 Schiebeler et al.
 2008/0275327 A1 11/2008 Faarbaek et al.
 2008/0275328 A1 11/2008 Jones et al.
 2008/0275349 A1 11/2008 Halperin et al.
 2008/0281376 A1 11/2008 Gerber et al.
 2008/0281381 A1 11/2008 Gerber et al.
 2008/0281550 A1 11/2008 Hogle et al.
 2008/0319281 A1 12/2008 Aarts et al.
 2009/0030345 A1 1/2009 Bonnet et al.
 2009/0040052 A1 2/2009 Cameron et al.
 2009/0054737 A1 2/2009 Magar et al.
 2009/0054742 A1 2/2009 Kaminska et al.
 2009/0060287 A1 3/2009 Hyde et al.
 2009/0076350 A1 3/2009 Bly et al.
 2009/0099624 A1 4/2009 Kokones et al.
 2009/0099627 A1 4/2009 Molnar et al.
 2009/0105785 A1 4/2009 Wei et al.
 2009/0137921 A1 5/2009 Kramer et al.
 2009/0227882 A1 9/2009 Foo
 2009/0227888 A1 9/2009 Salmi
 2009/0322540 A1 12/2009 Richardson et al.
 2010/0010382 A1 1/2010 Panken
 2010/0010392 A1 1/2010 Skelton et al.
 2010/0010583 A1 1/2010 Panken et al.
 2010/0023348 A1 1/2010 Hardee et al.
 2010/0056878 A1 3/2010 Partin et al.
 2010/0106217 A1 4/2010 Colborn
 2010/0109875 A1 5/2010 Ayon et al.
 2010/0121214 A1 5/2010 Giftakis et al.
 2010/0217533 A1 8/2010 Nadkarni et al.
 2010/0223020 A1 9/2010 Goetz
 2010/0228103 A1 9/2010 Schecter
 2010/0228314 A1 9/2010 Goetz
 2010/0268056 A1 10/2010 Picard et al.
 2010/0280336 A1 11/2010 Giftakis et al.
 2010/0280578 A1 11/2010 Skelton et al.
 2010/0280579 A1 11/2010 Denison et al.
 2010/0286567 A1 11/2010 Wolfe et al.

2010/0298661 A1 11/2010 McCombie et al.
 2010/0298742 A1 11/2010 Perlman et al.
 2010/0305665 A1 12/2010 Miesel et al.
 2010/0312188 A1 12/2010 Robertson et al.
 2011/0029044 A1 2/2011 Hyde et al.
 2011/0040204 A1 2/2011 Ivorra et al.
 2011/0040546 A1 2/2011 Gerber et al.
 2011/0060252 A1 3/2011 Simonsen et al.
 2011/0066062 A1 3/2011 Banet et al.
 2011/0066081 A1 3/2011 Goto et al.
 2011/0137372 A1 6/2011 Makous et al.
 2011/0172545 A1 7/2011 Grudic et al.
 2011/0230730 A1 9/2011 Quigg et al.
 2011/0245629 A1 10/2011 Giftakis et al.
 2011/0251468 A1* 10/2011 Osorio 600/300
 2011/0251469 A1 10/2011 Varadan
 2011/0270117 A1 11/2011 Warwick et al.
 2011/0270134 A1 11/2011 Skelton et al.
 2011/0295127 A1 12/2011 Sandler et al.
 2011/0306846 A1 12/2011 Osorio
 2011/0313484 A1 12/2011 Hincapie et al.

FOREIGN PATENT DOCUMENTS

GB	2026870	2/1980
GB	2079610	1/1982
WO	00/64336	11/2000
WO	2004/036377	4/2004
WO	2005/007120	1/2005
WO	2005/053788	6/2005
WO	2005/067599	7/2005
WO	2006/050144	5/2006
WO	2006/122148	11/2006
WO	2006134359	12/2006
WO	2007/066343	6/2007
WO	2007/072425	6/2007
WO	2007/124126	11/2007
WO	2007/124190	11/2007
WO	2007/124192	11/2007
WO	2007/142523	12/2007
WO	2008/045597	4/2008
WO	2011126931	10/2011

OTHER PUBLICATIONS

Borovikova, L.V., et al.; "Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin;" Letters to Nature; vol. 405; (May 2000); pp. 458-462.
 Brack, Kieran E., et al.; "Interaction Between Direct Sympathetic and Vagus Nerve Stimulation on Heart Rate in the Isolated Rabbit Heart;" Experimental Physiology vol. 89, No. 1; pp. 128-139.
 Chakravarthy, N., et al.; "Controlling Synchronization in a Neuron-Level Population Model;" International Journal of Neural Systems, vol. 17, No. 2 (2007) pp. 123-138.
 Clark, K.B., et al.; "Posttraining Electrical Stimulation of Vagal Afferents with Concomitant Vagal Efferent Inactivation Enhances Memory Storage Processes in the Rat;" Neurobiology of Learning and Memory, vol. 70, 364-373 (1998).
 Elmpt, W.J.C., et al.; "A Model of Heart Rate Changes to Detect Seizures in Severe Epilepsy" Seizure vol. 15, (2006) pp. 366-375.
 Frei, M.G., et al.; "Left Vagus Nerve Stimulation with the Neurocybernetic Prosthesis Has Complex Effects on Heart Rate and on Its Variability in Humans;" Epilepsia, vol. 42, No. 8 (2001); pp. 1007-1016.
 George, M.S., et al.; "Vagus Nerve Stimulation: A New Tool for Brain Research and Therapy;" Society of Biological Psychiatry vol. 47 (2000) pp. 287-295.
 "Heart Rate Variability—Standards of Measurement, Physiological Interpretation, and Clinical Use" Circulation-Electrophysiology vol. 93, No. 5; <http://circ.ahajournals.org/cgi/content-nw/full/93/5/1043/F3>.
 Henry, Thomas R.; "Therapeutic Mechanisms of Vague Name Stimulation;" Neurology, vol. 59 (Supp 4) (Sep. 2002), pp. S3-S14.
 Hallowitz et al., "Effects of Vagal Volleys on Units of Intralaminar and Juxtalaminar Thalamic Nuclei in Monkeys;" Brain Research, vol. 130 (1977), pp. 271-286.

(56)

References Cited

OTHER PUBLICATIONS

- Iasemidis, L.D., et al.; "Dynamical Resetting of the Human Brain at Epileptic Seizures: Application of Nonlinear Dynamics and Global Optimization Techniques;" IEEE Transactions on Biomedical Engineering, vol. 51, No. 3 (Mar. 2004); pp. 493-506.
- Iasemidis, L.D., et al.; "Spatiotemporal Transition to Epileptic Seizures: A Nonlinear Dynamical Analysis of Scalp and Intracranial EEG Recordings;" Spatiotemporal Models in Biological and Artificial Systems; F.L. Silva et al. (Eds.) IOS Press, 1997; pp. 81-88.
- Iasemidis, L.D.; "Epileptic Seizure Prediction and Control" IEEE Transactions on Biomedical Engineering, vol. 50, No. 5 (May 2003); pp. 549-558.
- Kautzner, J., et al.; "Utility of Short-Term Heart Rate Variability for Prediction of Sudden Cardiac Death After Acute Myocardial Infarction" Acta Univ. Palacki. Olomuc., Fac. Med., vol. 141 (1998) pp. 69-73.
- Koenig, S.A., et al.; "Vagus Nerve Stimulation Improves Severely Impaired Heart Rate Variability in a Patient with Lennox-Gastaut Syndrome" Seizure (2007) Article in Press—Yseiz-1305; pp. 1-4.
- Koo, B.; "EEG Changes With Vagus Nerve Stimulation" Journal of Clinical Neurophysiology, vol. 18 No. 5 (Sep. 2001); pp. 434-441.
- Krittayaphong, M.D., et al.; "Heart Rate Variability in Patients with Coronary Artery Disease: Differences in Patients with Higher and Lower Depression Scores" Psychosomatic Medicine vol. 59 (1997) pp. 231-235.
- Leutmezer, F., et al.; "Electrocardiographic Changes at the Onset of Epileptic Seizures;" Epilepsia, vol. 44, No. 3; (2003); pp. 348-354.
- Lewis, M.E., et al.; "Vagus Nerve Stimulation Decreases Left Ventricular Contractility in Vivo in the Human and Pig Heart" The Journal of Physiology vol. 534, No. 2, (2001) pp. 547-552.
- Li, M., et al.; "Vagal Nerve Stimulation Markedly Improves Long-Term Survival After Chronic Heart Failure in Rats;" Circulation (Jan. 2004) pp. 120-124.
- Licht, C.M.M.; Association Between Major Depressive Disorder and Heart Rate Variability in the Netherlands Study of Depression and Anxiety (NESDA); Arch. Gen Psychiatry, vol. 65, No. 12 (Dec. 2008); pp. 1358-1367.
- Lockard et al.; "Feasibility and Safety of Vagal Stimulation in Monkey Model;" Epilepsia, vol. 31 (Supp. 2) (1990), pp. S20-S26.
- McClintock, P.; "Can Noise Actually Boost Brain Power" Physics World Jul. 2002; pp. 20-21.
- Mori, T., et al.; "Noise-Induced Entrainment and Stochastic Resonance in Human Brain Waves" Physical Review Letters vol. 88, No. 21 (2002); pp. 218101-1-218101-4.
- Mormann, F.; "Seizure prediction: the long and winding road," Brain 130 (2007), 314-333.
- Nouri, M.D.; "Epilepsy and the Autonomic Nervous System" emedicine (updated May 5, 2006); pp. 1-14; <http://www.emedicine.com/neuro/topic658.htm>.
- O'Regan, M.E., et al.; "Abnormalities in Cardiac and Respiratory Function Observed During Seizures in Childhood" Developmental Medicine & Child Neurology, vol. 47 (2005) pp. 4-9.
- Pathwardhan, R.V., et al.; Control of Refractory status epilepticus precipitated by anticonvulsant withdrawal using left vagal nerve stimulation: a case report, Surgical Neurology 64 (2005) 170-73.
- Poddubnaya, E.P.; "Complex Estimation of Adaptation Abilities of the Organism in Children Using the Indices of Responsiveness of the Cardiovascular System and Characteristics of EEG" Neurophysiology vol. 38, No. 1 (2006); pp. 63-74.
- Rugg-Gunn, F.J., et al.; "Cardiac Arrhythmias in Focal Epilepsy: a Prospective Long-Term Study" www.thelancet.com vol. 364 (2004) pp. 2212-2219.
- Sajadieh, A., et al.; "Increased Heart Rate and Reduced Heart-Rate Variability are Associated with Subclinical Inflammation in Middle-Aged and Elderly Subjects with No Apparent Heart Disease" European Heart Journal vol. 25, (2004); pp. 363-370.
- Scherthaner, C., et al.; "Autonomic Epilepsy—The Influence of Epileptic Discharges on Heart Rate and Rhythm" The Middle European Journal of Medicine vol. 111, No. 10 (1999) pp. 392-401.
- Terry et al.; "The Implantable Neurocybernetic Prosthesis System", Pacing and Clinical Electrophysiology, vol. 14, No. 1 (Jan. 1991), pp. 86-93.
- Tubbs, R.S., et al.; "Left-Sided Vagus Nerve Stimulation Decreases Intracranial Pressure Without Resultant Bradycardia in the Pig: A Potential Therapeutic Modality for Humans" Child's Nervous System Original Paper; Springer-Verlag 2004.
- Umetani, M.D., et al.; "Twenty-Four Hour Time Domain Heart Rate Variability and Heart Rate: Relations to Age and Gender Over Nine Decades" JACC vol. 31, No. 3; (Mar. 1998); pp. 593-601.
- Vonck, K., et al. "The Mechanism of Action of Vagus Nerve Stimulation for Refractory Epilepsy—The Current Status", Journal of Neurophysiology, vol. 18 No. 5 (2001), pp. 394-401.
- Woodbury, et al.; "Vagal Stimulation Reduces the Severity of Maximal Electroshock Seizures in Intact Rats. Use of a Cuff Electrode for Stimulating and Recording"; Pacing and Clinical Electrophysiology, vol. 14 (Jan. 1991), pp. 94-107.
- Zabara, J.; "Neuroinhibition of Xylazine Induced Emesis" Pharmacology & Toxicology, vol. 63 (1988) pp. 70-74.
- Zabara, J. "Inhibition of Experimental Seizures in Canines by Repetitive Vagal Stimulation" Epilepsia vol. 33, No. 6 (1992); pp. 1005-1012.
- Zabara, J., et al.; "Neural Control of Circulation I" The Physiologist, vol. 28 No. 4 (1985); 1 page.
- Zabara, J., et al.; "Neuroinhibition in the Regulation of Emesis" Space Life Sciences, vol. 3 (1972) pp. 282-292.
- Osorio, Ivan et al., "An Introduction to Contingent (Closed-Loop) Brain Electrical Stimulation for Seizure Blockage, To Ultra-Short-Term Clinical Trials, and to Multidimensional Statistical Analysis of Therapeutic Efficacy," Journal of Clinical Neurophysiology, vol. 18, No. 6, pp. 533-544, 2001.
- Osorio, Ivan et al., "Automated Seizure Abatement in Humans Using Electrical Stimulation," Annals of Neurology, vol. 57, No. 2, pp. 258-268, 2005.
- Sunderam, Sridhar et al., "Vagal and Sciatic Nerve Stimulation Have Complex, Time-Dependent Effects on Chemically-Induced Seizures: A Controlled Study," Brain Research, vol. 918, pp. 60-66, 2001.
- Weil, Sabine et al., "Heart Rate Increase in Otherwise Subclinical Seizures Is Different in Temporal Versus Extratemporal Seizure Onset: Support for Temporal Lobe Automatic Influence," Epileptic Disord., vol. 7, No. 3, Sep. 2005, pp. 199-204.
- Digenarro, Giancarlo et al., "Ictal Heart Rate Increase Precedes EEG Discharge in Drug-Resistant Mesial Temporal Lobe Seizures," Clinical Neurophysiology, No. 115, 2004, pp. 1169-1177.
- Zijlmans, Maeike et al., "Heart Rate Changes and ECG Abnormalities During Epileptic Seizures: Prevalence and Definition of an Objective Clinical Sign," Epilepsia, vol. 43, No. 8, 2002, pp. 847-854.
- O'Donovan, Cormac A. et al., "Computerized Seizure Detection Based on Heart Rate Changes," abstract of AES Proceedings, Epilepsia, vol. 36, Suppl. 4, 1995, p. 7.
- Robinson, Stephen E et al., "Heart Rate Variability Changes As Predictor of Response to Vagal Nerve Stimulation Therapy for Epilepsy," abstract of AES Proceedings, Epilepsia, vol. 40, Suppl. 7, 1999, p. 147.
- Long, Teresa J. et al., "Effectiveness of Heart Rate Seizure Detection Compared to EEG in an Epilepsy Monitoring Unit (EMU)," abstract of AES Proceedings, Epilepsia, vol. 40, Suppl. 7, 1999, p. 174.
- PCT Search Report and Written Opinion for International Application No. PCT/US2011/054287, dated Mar. 12, 2012, 18 pages.

* cited by examiner




FIGURE 1




FIGURE 2




FIGURE 3A




FIGURE 3B




FIGURE 3C




FIGURE 4
Not to scale






FIGURE 5



Not to scale

FIGURE 6






FIGURE 8




FIGURE 9

1

DETECTING, QUANTIFYING, AND/OR CLASSIFYING SEIZURES USING MULTIMODAL DATA

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation application of U.S. patent application Ser. No. 12/896,525, filed Oct. 1, 2010. U.S. patent application Ser. No. 12/896,525 is hereby incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention relates to medical device systems and methods capable of detecting and, in some embodiments, treating an occurring or impending seizure using multimodal data.

DESCRIPTION OF THE RELATED ART

Of the approximately 60 million people worldwide affected with epilepsy, roughly 23 million people suffer from epilepsy resistant to multiple medications. In the USA alone, the annual cost of epilepsy care is USD 12 billion (in 1995 dollars), most of which is attributable to subjects with pharmaco-resistant seizures. Pharmaco-resistant seizures are associated with an increase mortality and morbidity (e.g., compared to the general population and to epileptics whose seizures are controlled by medications) and with markedly degraded quality of life for patients. Seizures may impair motor control, responsiveness to a wide class of stimuli, and other cognitive functions. The sudden onset of a patient's impairment of motor control, responsiveness, and other cognitive functions precludes the performance of necessary and even simple daily life tasks such as driving a vehicle, cooking, or operating machinery, as well as more complex tasks such as acquiring knowledge and socializing.

Therapies using electrical currents or fields to provide a therapy to a patient (electrotherapy) are beneficial for certain neurological disorders, such as epilepsy. Implantable medical devices have been effectively used to deliver therapeutic electrical stimulation to various portions of the human body (e.g., the vagus nerve) for treating epilepsy. As used herein, "stimulation," "neurostimulation," "stimulation signal," "therapeutic signal," or "neurostimulation signal" refers to the direct or indirect application of an electrical, mechanical, magnetic, electro-magnetic, photonic, acoustic, cognitive, and/or chemical signal to an organ or a neural structure in the patient's body. The signal is an exogenous signal that is distinct from the endogenous electro-chemical activity inherent to the patient's body and also from that found in the environment. In other words, the stimulation signal (whether electrical, mechanical, magnetic, electro-magnetic, photonic, acoustic, cognitive, and/or chemical in nature) applied to a cranial nerve or to other nervous tissue structure in the present invention is a signal applied from a medical device, e.g., a neurostimulator.

A "therapeutic signal" refers to a stimulation signal delivered to a patient's body with the intent of treating a medical condition through a suppressing (e.g., blocking) or modulating effect to neural tissue. The effect of a stimulation signal on neuronal activity may be suppressing or modulating; however, for simplicity, the terms "stimulating", suppressing, and modulating, and variants thereof, are sometimes used interchangeably herein. In general, however, the delivery of an exogenous signal itself refers to "stimulation" of an organ or a neural structure, while the effects of that signal, if any, on the

2

electrical activity of the neural structure are properly referred to as suppression or modulation.

Depending upon myriad factors such as the history (recent and distant) of the nervous system, stimulation parameters and time of day, to name a few, the effects of stimulation upon the neural tissue may be excitatory or inhibitory, facilitatory or disfacilitatory and may suppress, enhance, or leave unaltered neuronal activity. For example, the suppressing effect of a stimulation signal on neural tissue would manifest as the blockage of abnormal activity (e.g., epileptic seizures) see Osorio et al., *Ann Neurol* 2005; Osorio & Frei *IJNS* 2009) The mechanisms thorough which this suppressing effect takes place are described in the foregoing articles. Suppression of abnormal neural activity is generally a threshold or suprathreshold process and the temporal scale over which it occurs is usually in the order of tens or hundreds of milliseconds. Modulation of abnormal or undesirable neural activity is typically a "sub-threshold" process in the spatio-temporal domain that may summate and result under certain conditions, in threshold or suprathreshold neural events. The temporal scale of modulation is usually longer than that of suppression, encompassing seconds to hours, even months. In addition to inhibition or dysfacilitation, modification of neural activity (e.g., wave annihilation) may be exerted through collision with identical, similar or dissimilar waves, a concept borrowed from wave mechanics, or through phase resetting (Winfree).

In some cases, electrotherapy may be provided by implanting an electrical device, i.e., an implantable medical device (IMD), inside a patient's body for stimulation of a nervous tissue, such as a cranial nerve. Generally, electrotherapy signals that suppress or modulate neural activity are delivered by the IMD via one or more leads. When applicable, the leads generally terminate at their distal ends in one or more electrodes, and the electrodes, in turn, are coupled to a target tissue in the patient's body. For example, a number of electrodes may be attached to various points of a nerve or other tissue inside a human body for delivery of a neurostimulation signal.

While contingent (also referred to as "closed-loop," "active," or "feedback" stimulation (i.e., electrotherapy applied in response to sensed information, such as heart rate) stimulation schemes have been proposed, non-contingent, programmed periodic stimulation is the prevailing modality. For example, vagus nerve stimulation for the treatment of epilepsy usually involves a series of grouped electrical pulses defined by an "on-time" (such as 30 sec.) and an "off-time" (such as 5 min.). This type of stimulation is also referred to as "open-loop," "passive," or "non-feedback" stimulation. Each sequence of pulses during an on-time may be referred to as a "pulse burst." The burst is followed by the off-time period in which no signals are applied to the nerve. During the on-time, electrical pulses of a defined electrical current (e.g., 0.5-3.5 milliamps) and pulse width (e.g., 0.25-1.0 milliseconds) are delivered at a defined frequency (e.g., 20-30 Hz) for a certain duration (e.g., 10-60 seconds). The on-time and off-time parameters together define a duty cycle, which is the ratio of the on-time to the sum of the on-time and off-time, and which describes the fraction of time that the electrical signal is applied to the nerve.

In VNS, the on-time and off-time may be programmed to define an intermittent pattern in which a repeating series of electrical pulse bursts are generated and applied to a cranial nerve such as the vagus nerve. The off-time is provided to minimize adverse effects and conserve power. If the off-time is set at zero, the electrical signal in conventional VNS may provide continuous stimulation to the vagus nerve. Alterna-

tively, the off time may be as long as one day or more, in which case the pulse bursts are provided only once per day or at even longer intervals. Typically, however, the ratio of “off-time” to “on-time” may range from about 0.5 to about 10.

In addition to the on-time and off-time, the other parameters defining the electrical signal in VNS may be programmed over a range of values. The pulse width for the pulses in a pulse burst of conventional VNS may be set to a value not greater than about 1 msec, such as about 250-500 μ sec, and the number of pulses in a pulse burst is typically set by programming a frequency in a range of about 20-300 Hz (i.e., 20 pulses per second to 300 pulses per second). A non-uniform frequency may also be used. Frequency may be altered during a pulse burst by either a frequency sweep from a low frequency to a high frequency, or vice versa. Alternatively, the timing between adjacent individual signals within a burst may be randomly changed such that two adjacent signals may be generated at any frequency within a range of frequencies.

Although neurostimulation has proven effective in the treatment of a number of medical conditions, it would be desirable to further enhance and optimize neurostimulation-based therapy for this purpose. For example, it may be desirable to detect an occurring or impending seizure. Such detection may be useful in triggering a therapy, monitoring the course of a patient’s disease, or the progress of his or her treatment thereof. Alternatively or in addition, such detection may be useful in warning the patient of an impending seizure or alerting the patient, a physician, a caregiver, or a suitably programmed computer in order for that person or computer program to take action intended to reduce the likelihood, duration, or severity of the seizure or impending seizure, or to facilitate further medical treatment or intervention for the patient. In particular, detection of an occurring or impending seizure enables the use of contingent neurostimulation. The state of the art does not provide an efficient and effective means for performing such detection and/or warning. Conventional VNS stimulation as described above does not detect occurring or impending seizures.

Closed-loop neurostimulation therapies for treating epilepsy have been proposed in which stimulation is triggered based upon factors including EEG activity (see, e.g., U.S. Pat. No. 5,995,868 and U.S. Pat. No. 7,280,867) as well as cardiac-based activity (see, e.g., U.S. Pat. No. 6,961,618 and U.S. Pat. No. 5,928,272). EEG- or ECoG-based approaches involving recording of neural electrical activity at any spatio-temporal scale involve determination of one or more parameters from brain electrical activity that indicate a seizure. Such approaches have met with limited success and have a number of drawbacks, including highly invasive and technically demanding and costly surgery for implanted systems, and the poor patient compliance for external systems (which require the patient to wear electrodes on the scalp for extended periods).

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a method for detecting an epileptic event based upon multimodal signals such as an autonomic signal and a neurologic signal of a patient. In one embodiment, the method comprises providing an autonomic signal indicative of the patient’s autonomic activity; providing a neurologic signal indicative of the patient’s neurological activity; and detecting an epileptic event based upon the autonomic signal and the neurologic signal.

In one embodiment the autonomic signal is a cardiac signal, and the neurologic signal is a kinetic signal. In another embodiment, a first autonomic signal is a respiratory signal and a second autonomic signal is a dermal signal (e.g., sweat glands). In yet another embodiment, the autonomic signal is a cardiac signal, the neurologic signal is included, and a metabolic signal is included.

In one embodiment, the present invention provides a computer readable program storage device encoded with instructions that, when executed by a computer, performs a method for detecting an epileptic event based upon a patient’s cardiac signal and kinetic activity. The method includes: providing a kinetic signal indicative of a body movement of the patient; calculating based on the kinetic signal a kinetic score indicative of a correlation of said kinetic signal with an epileptic event; detecting an epileptic event based upon the patient’s heart beat sequence; and providing an output indicative of an epileptic event based on the kinetic score.

In another embodiment, the present invention provides a computer readable program storage device encoded with instructions that, when executed by a computer, performs a method for detecting an epileptic event based upon a patient’s cardiac signal and kinetic activity. The method includes: providing a kinetic signal indicative of a body movement of the patient; classifying the kinetic signal as either an epileptic event kinetic signal or a nonepileptic event kinetic signal; detecting an epileptic event based upon changes in the patient’s heart beat sequence; confirming the detecting if said kinetic signal is classified as an epileptic event kinetic signal; overriding the detecting if said kinetic signal is classified as a nonepileptic event kinetic signal; and providing an output indicative of an epileptic event only if the detecting is confirmed.

In yet another embodiment, the present invention provides an implantable medical device for detecting an epileptic event based upon an autonomic signal and a neurologic signal of a patient. The implantable medical device includes a detection module for receiving an autonomic signal indicative of the patient’s autonomic activity and for receiving a neurologic signal indicative of the patient’s neurological activity. The implantable medical device also includes a processing element for determining whether an epileptic event has occurred based upon the autonomic signal and the neurologic signal.

In one embodiment, the present invention provides a method for detecting a primarily or secondarily generalized tonic-clonic seizure based upon two or more of a patient’s body signals. In one embodiment, the method comprises providing at least two body signals selected from the group consisting of a cardiac signal indicative of the patient’s heart beats; an accelerometer signal indicative of the patient’s movement; an inclinometer signal indicative of the patient’s body position; an actigraph signal indicative of the patient’s movement, body position, or both; a respiratory signal indicative of the patient’s respiration; a skin resistivity signal indicative of the patient’s skin resistivity; an blood gas signal indicative of the patient’s blood oxygen content, carbon dioxide content, or both; a blood pH signal indicative of the patient’s blood pH; an isometric force signal indicative of the patient’s muscle activity; a sound signal indicative of the patient’s oral utterances or vocalizations; an ocular signal indicative of the patient’s eye movement; a responsiveness signal indicative of the patient’s responsiveness; an awareness signal indicative of the patient’s awareness; and a stress marker signal indicative of at least one stress marker of the patient; and detecting the generalized tonic-clonic epileptic seizure based upon the timewise correlation of two features, one feature being of each of the at least two body signals,

wherein the feature of the cardiac signal is an increase in the patient's heart rate above a reference value; the feature of the accelerometer signal is an increase in the patient's movement above a reference value followed by a decrease in the patient's movement below a reference value; the feature of the inclinometer signal is a change of the patient's body position indicative of a fall; the feature of the respiratory signal is a respiration rate outside of an interictal reference range; the feature of the skin resistivity signal is a decrease in the patient's skin resistivity below a reference value; the feature of the blood gas signal is a decrease in the patient's blood oxygen content below a reference value, an increase in carbon dioxide content above a reference value, or both; the feature of the blood pH signal is a decrease in the patient's blood pH below a reference value; the feature of the isometric force signal is an increase in the patient's muscle activity above a reference value; the feature of the sound signal is an increase in the patient's oral utterances or vocalizations indicative of an epileptic cry; the feature of the ocular signal is an increase in the patient's eye movement above a reference value; the feature of the responsiveness signal is a decrease in the patient's responsiveness below a reference value; the feature of the awareness signal is a decrease in the patient's awareness below a reference value; and the feature of the stress marker signal is an increase in at least one stress marker of the patient above a reference value.

In one embodiment, the present invention also provides a computer readable program storage device encoded with instructions that, when executed by a computer, performs a method for detecting a partial epileptic seizure based upon two or more of a patient's body signals. In one embodiment, this method comprises providing at least two body signals selected from the group consisting of a cardiac signal indicative of the patient's heart beats; an accelerometer signal indicative of the patient's movement; an inclinometer signal indicative of the patient's body position; an actigraph signal indicative of the patient's movement, body position, or both; a respiratory signal indicative of the patient's respiration; a skin resistivity signal indicative of the patient's skin resistivity; an blood gas signal indicative of the patient's blood oxygen content, carbon dioxide content, or both; a blood pH signal indicative of the patient's blood pH; a sound signal indicative of the patient's oral utterances or vocalizations; a responsiveness signal indicative of the patient's responsiveness; an awareness signal indicative of the patient's awareness; and a stress marker signal indicative of at least one stress marker of the patient; and detecting the partial epileptic seizure based upon the timewise correlation of two features, one feature being of each of the at least two body signals, wherein the feature of the cardiac signal is a heart rate outside an interictal reference value range; the feature of the accelerometer signal is a movement velocity outside an interictal reference value range; the feature of the respiratory signal is a respiration rate, tidal volume, minute volume, or pattern outside of an interictal reference value range; the feature of the skin resistivity signal is a skin resistivity outside an interictal reference value range; the feature of the blood gas signal is an increase in the patient's blood oxygen content above an interictal reference value, a decrease in carbon dioxide content below an interictal reference value, or both; the feature of the blood pH signal is a blood pH outside an interictal reference value range; the feature of the sound signal is a change in the pattern, loudness, timbre or quality, semantic content and contextual relevance of the patient's oral utterances or vocalizations compared to utterances or vocalizations to the non-

seizure state; and the feature of the stress marker signal is a concentration of at least one stress marker outside an interictal reference value range.

In yet another aspect of the present invention, a computer readable program storage device is provided that is encoded with instructions that, when executed by a computer, perform a method described above.

In one embodiment, a medical device is provided comprising an autonomic signal module, a kinetic signal module, a detection module, and a processor adapted to perform a method as described above.

In yet another aspect of the present invention, a medical device system for detecting an epileptic event based upon multimodal signals, is provided. The medical device system includes a sensor for detecting a first modal data and a second modal data relating to a patient's body. The first modal data includes an autonomic signal and the second modal data includes a neurologic signal of the patient's body. The medical device system also includes an implantable medical device (IMD) operatively coupled to the sensor(s). The implantable medical device includes: a neurologic signal module for receiving the neurologic signal; an autonomic signal module for receiving the autonomic signal; and a processing element for determining whether an epileptic event has occurred based upon the first and second modal data.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention may be understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements, and in which:

FIG. 1 provides a stylized diagram of a medical device implanted into a patient's body for providing a therapeutic signal to a structure of the patient's body, in accordance with one illustrative embodiment of the present invention;

FIG. 2 provides a block diagram of a medical device system that includes a medical device and an external unit, in accordance with one illustrative embodiment of the present invention;

FIG. 3A provides a block diagram of a cardiac signal module of a medical device, in accordance with one illustrative embodiment of the present invention;

FIG. 3B provides a block diagram of a kinetic signal module of a medical device, in accordance with one illustrative embodiment of the present invention;

FIG. 3C provides a block diagram of a detection module of a medical device, in accordance with one illustrative embodiment of the present invention;

FIG. 4 shows the time of appearance (relative to clinical onset, dashed vertical line) and direction of deviations from reference activity of a plurality of body signals for four seizure types, specifically, absence seizures, tonic-clonic seizures, and simple or complex partial seizures;

FIG. 5 shows time courses (relative to clinical onset, dashed vertical line) of activity of a plurality of body signals for tonic-clonic seizures;

FIG. 6 shows time courses (relative to clinical onset, dashed vertical line) of activity of a plurality of body signals for partial (simple or complex) seizures;

FIG. 7 shows time courses (relative to clinical onset, dashed vertical line) of activity of a plurality of body signals for idiopathic absence seizures;

FIG. 8 shows (A) an exemplary two-dimensional plot of a trajectory of epileptic movements, (B) an exemplary three-

dimensional plot of epileptic movements, and (C) an additional exemplary three-dimensional plot of epileptic movements; and

FIG. 9 shows three two-dimensional, temporally cumulative plots of discrete movements during the clonic phase of a primarily or secondarily generalized tonic-clonic seizure.

While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.

DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

Illustrative embodiments of the invention are described herein. In the interest of clarity, not all features of an actual implementation are described in this specification. In the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the design-specific goals, which will vary from one implementation to another. It will be appreciated that such a development effort, while possibly complex and time-consuming, would nevertheless be a routine undertaking for persons of ordinary skill in the art having the benefit of this disclosure.

This document does not intend to distinguish between components that differ in name but not function. In the following discussion and in the claims, the terms “including” and “includes” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to.” Also, the term “couple” or “couples” is intended to mean either a direct or an indirect electrical connection. “Direct contact,” “direct attachment,” or providing a “direct coupling” indicates that a surface of a first element contacts the surface of a second element with no substantial attenuating medium there between. The presence of small quantities of substances, such as bodily fluids, that do not substantially attenuate electrical connections does not vitiate direct contact. The word “or” is used in the inclusive sense (i.e., “and/or”) unless a specific use to the contrary is explicitly stated.

The term “electrode” or “electrodes” described herein may refer to one or more stimulation electrodes (i.e., electrodes for delivering a therapeutic signal generated by an IMD to a tissue), sensing electrodes (i.e., electrodes for sensing a physiological indication of a state of a patient’s body), and/or electrodes that are capable of delivering a therapeutic signal, as well as performing a sensing function.

Identification of changes in brain state (whether physiologic or pathologic) has traditionally been accomplished through analysis of electrical brain signals and behavioral observation. Continuous (e.g., round-the-clock) automated monitoring of changes in brain state imposes certain limitations on the utilization of these traditional methods, due to the difficulties inherent to automated ambulatory video, the large amount of data produced per unit time, and the excessive demands on human and technical resources required to maintain an acceptable signal/noise for electrical signals recorded from the scalp. Additionally, scalp signals have poor temporal-spatial resolution, a characteristic which results in both low sensitivity and specificity of state-of-brain detection changes.

Implanted sensors or electrodes beneath the scalp but above the outer skull table or intra-cranial (epidural, subdural

or depth) have been used to overcome the limitations of scalp recordings. However, although the quality of recordings (especially for intracranial electrodes) is much better (e.g., typically has a higher S/N) than that from scalp electrodes, the quality is still limited and there are risks (e.g., infection, bleeding, brain damage) associated with these devices, not to mention cost and scarcity of neurosurgeons to perform this type of procedures.

While electrical brain signals and behavioral observation may provide information for classification of brain states, this task can be accomplished more efficiently, more precisely, and/or more cost-effectively through monitoring of other biological signals such those generated by the heart, muscle, skin, eyes, tympanic membrane temperature, and body posture/movement, since they may not require surgery, or if surgery is required for implantation, the procedures are much shorter, simpler, and cheaper than those required for recording of brain signals and there is no shortage of human resources.

Certain highly valuable neurological signals (e.g., cognitive) for detection, quantification, and classification of state changes may be obtained non-invasively and can be used in this invention.

These multi-modal (e.g., autonomic, neurologic, etc) signals can be used individually or in combination to monitor continuously the brain and generate a state-of-the-system/organ report, in real-time for the detection, quantification, classification, validation, control and logging of physiologic or pathologic state changes. This approach takes advantage of the inherent and finely tuned dynamical coupling among these systems. For instance, changes in brain state/activity may result in changes in heart activity, muscle activity, and skin properties.

Herein, Applicant describes a method, systems, and devices that may: a) detect in real-time pre-specified changes in brain state; b) quantify their duration, intensity, and time of occurrence; c) classify their type (e.g., epileptic vs. non-epileptic seizures; primarily vs. secondarily generalized seizures; generalized vs. partial seizures; complex vs., simple partial seizures; d) use as a basis for warning and control/therapy, and/or e) save this information to memory for future retrieval for optimization of detection, quantification and classification of state changes and assessment and optimization of therapeutic (e.g., control) efficacy. Non-epileptic movements in this invention refer to those resembling movements seen during tonic-clonic seizures but which are not caused by those seizures.

Herein, “multimodal” refers to epileptic event detection based on more than one endogenous mode or type of signal. The multimodal epileptic event detection disclosed herein provides a comprehensive, cost-effective, valuable alternative to systems of epileptic event detection exclusively based on brain electrical signals such as EEG. To date, no multimodal systems have been developed or commercialized. Multimodal epileptic event detection may make use of signals or markers of autonomic, neurologic, endocrine, metabolic, gastro-intestinal, and/or dermal origin and of tissue/organ stress, such as those presented in Table 1.

Multimodal detection of state changes takes advantage of the fact that certain brain structures directly or indirectly influence autonomic, endocrine, gastro-intestinal, dermal and metabolic functions and that certain abnormal states (e.g. seizures) stress the body tissues and result in the elevation of certain compounds or molecules (e.g., stress markers) that may be used to detect and verify the occurrence of said abnormal state.

It has been established that seizures in humans originating from or spreading to central autonomic structures induce

changes in heart rate, among other cardio-vascular indices. It should be stated that seizure-induced heart rate increases (which are far more frequent than heart rate decreases) are not primarily the result of increased motor activity or of metabolic changes, but are instead a neurogenic phenomenon. In the present invention, a highly robust, efficient and reliable system is provided for detecting, quantifying and/or classifying epileptic seizures based upon multi-modal signals and, if desired, using this information to provide warnings, therapies and optimization of all of these tasks. Systems of the present invention are suitable for commercial, long-term implants or external devices and provide reliable and accurate indications of seizure events for a wide variety of epilepsy patients.

TABLE 1

Multimodal Signals
Autonomic
Cardiac: EKG, PKG, Echocardiography, Apexcardiography (ApKG), Intra-cardiac pressure, Cardiac blood flow, cardiac thermography; from which can be derived, e.g., heart rate (HR), change of HR, rate of change of HR, heart rate variability (HRV), change of HRV, rate of change of HRV, HRV vs. HR. Also, blood pressure, heart sounds, heart rhythm, heartbeat wave morphology, heartbeat complex morphology, and thoracic wall deflection.
Vascular: Arterial Pressure, Arterial and venous blood wave pressure morphology; Arterial and venous blood flow velocity, arterial and venous blood flow sounds, arterial and venous thermography
Respiratory: Frequency, tidal volume, minute volume, respiratory wave morphology, respiratory sounds, end-tidal CO ₂ , Intercostal EMG, Diaphragmatic EMG, chest wall and abdominal wall motion, from which can be derived, e.g., respiration rate (RR), change of RR, rate of change of RR. Also, arterial gas concentrations, including oxygen saturation, as well as blood pH can be considered respiratory signals.
Dermal: Skin resistance, skin temperature, skin blood flow, sweat gland activity
Concentrations of catecholamines (and their metabolites) and acetylcholine or acetylcholinesterase activity in blood, saliva and other body fluids concentrations and its rate of change.
Neurologic
Cognitive/behavioral: Level of consciousness, attention, reaction time, memory, visuo-spatial, language, reasoning, judgment, mathematical calculations, auditory and/or visual discrimination
Kinetic: Direction, speed/acceleration, trajectory (1D to 3D), pattern, and quality of movements, force of contraction, body posture, body orientation/position, body part orientation/position in reference to each other and to imaginary axes, muscle tone, agonist-to-antagonist muscle tone relation, from which can be derived, e.g., information about gait, posture, accessory movements, falls
Vocalizations: Formed, unformed
EEG/ECOG, Evoked potentials, field potentials, single unit activity
Endocrine: Prolactin, luteinizing hormone, follicle stimulation hormone, growth hormone, ACTH, cortisol, vasopressin, beta-endorphin, beta, lipotropin-, corticotropin-releasing factor (CRF)
Stress Markers: Reactive oxygen and nitrogen species including but not limited to iso- and neuro-prostanes and nitrite/nitrate ratio, glutathione, glutathione disulfide and glutathione peroxidase activity, citrulline, protein carbonyls, thiobarbituric acid, the heat shock protein family, catecholamines, lactic acid, N-acetylaspartate, and metabolites of any of the foregoing.
Metabolic: arterial pH and gases, lactate/pyruvate ratio, electrolytes, glucose

In one embodiment, the present invention relates to a method for detecting an epileptic event based upon an autonomic signal (e.g., a cardiac signal) and a neurologic signal (e.g., a kinetic signal) of a patient, comprising providing an autonomic signal indicative of the patient's autonomic activity; providing a neurologic signal indicative of the patient's neurological activity; detecting an epileptic event based upon the autonomic signal and the neurologic signal.

"Epileptic event" refers to a seizure, a period of increased likelihood of a seizure, a pre-ictal period, or a post-ictal period, among others.

Any autonomic signal indicative of the patient's autonomic activity can be used in the method. In one embodiment, the autonomic signal is selected from the group consisting of a cardiac signal, a respiratory signal, a skin resistivity signal, an eye signal, a blood signal, and two or more thereof. The autonomic signal can be provided by an electrocardiogram (EKG) device, a pupillometer, a face or body temperature monitor, a skin resistance monitor, a sound sensor, a pressure sensor, a blood gas sensor, among others, or two or more thereof.

Any neurologic signal indicative of the patient's neurologic activity can be used in the method. In one embodiment, the neurologic signal is selected from the group consisting of a brain signal, a kinetic signal, and two or more thereof. The neurologic signal can be provided by an electroencephalography (EEG) device, an electrocorticography (ECoG) device, an accelerometer, an inclinometer, an actigraph, a responsiveness testing device or system, among others, or two or more thereof.

An epileptic event can be detected based upon the autonomic signal and the neurologic signal. The partial basis upon the autonomic signal can make use of techniques described in other patents or patent applications, such as U.S. Pat. Nos. 5,928,272; 7,643,881; U.S. patent application Ser. No. 12/770,562, which are hereby incorporated herein by reference. The partial basis upon the neurologic signal can make use of techniques described in other patents or patent applications, such as U.S. Pat. No. 7,630,757, which are hereby incorporated herein by reference.

In one embodiment, when the autonomic signal is a cardiac signal, the detection can be partially based on the observation that some seizure types are associated with a change (e.g., increase) in heart rate compared to a reference heart rate value range, such as a range of measures of central tendency of heart rate over a short or relatively long time window. Some other seizure types are associated with a decrease in heart rate above a reference heart rate value (see for example, FIG. 4).

Generally, when the term "reference value" is used herein without further qualification, it refers to a value derived from an interictal period. Reference values or ranges thereof for any of the autonomic, neurologic, endocrine, metabolic or stress marker features are day of time (e.g., circadian) and state (e.g., resting wakefulness) dependent and thus non-stationary. Although reference values for a certain feature in a certain state or time are most directly comparable to corresponding signals in the same state or time, they may be comparable to corresponding signals from other states, times, or both.

As used in FIGS. 4-7, clinical onset refers to the earlier of either a) when a patient notices a first seizure symptom, or b) when an expert observer (or a person familiar with the patient's seizures) observes a first change indicative of the seizure. It must be underscored that while the most apparent change may be the "first" to be noticed by the patient or seen by the observer, this change may have been preceded by other (unnoticed or unobserved) changes, and that the "first change" defining the seizure onset may not be the first change actually occurring and associated with the seizure. Only one of several indicia or signs of a seizure may be clinically recognizable, and the clinical onset time is thus given or determined by this clinically recognizable sign or symptom. This does not preclude other clinical symptoms having occurred prior to the clinically recognizable sign or symptom. This is illustrated, for example, in FIG. 6, in which the onset

of impaired responsiveness precedes, by a few seconds, the clinical onset, and where the EKG and respiratory changes are also shown as occurring before clinical onset.

FIG. 4 shows the time of appearance (relative to clinical onset, dashed vertical line) and direction of deviations from interictal reference activity, of a plurality of body signals for four seizure types: specifically, absence seizures, generalized tonic-clonic seizures (whether primarily or secondarily generalized), and simple or complex partial seizures. The horizontal arrows show the times of appearance of the symptom change in reference to clinical onset as defined in the present application. A dot without horizontal arrows indicates that the most important aspect of the signal change occurs at clinical onset. This does not exclude the possibility that this change may reappear or change direction at some later time. Upward vertical arrows indicate an increase in the value of the signal while downwards arrows indicate a decrease in value. Arrow length does not reflect a scale or magnitude of the change. When multiple deviations are shown, the larger, thicker arrow is the one most commonly seen over general patient populations. Of course, the skilled epileptologist is aware that some patients will show one or more variations from the typical cases shown in FIG. 4.

To facilitate understanding, certain important details about certain body signals, their onset, and temporal evolution in reference to clinical onset (dashed lines) have been omitted from FIGS. 4-7. These figures should be viewed only as illustrative of the changes in body signals that occur with the various seizure classes.

For example, tonic-clonic seizures are often correlated with an increase in heart rate beginning at about seizure onset (see for example, FIG. 5).

For another example, partial seizures are often correlated with an increase in heart rate beginning before, at, or shortly after electrographic seizure onset. The increase is less than that associated with tonic-clonic seizures (see for example, FIG. 6).

In another embodiment, when the autonomic signal is a respiratory signal, the detection can be partially based on the observation that some seizure types are associated with a deviation of the respiration rate from a reference respiration rate value range (see for example, FIG. 4).

For example, partial seizures are often correlated with increases in respiration rate (see for example, FIG. 6).

In one embodiment, when the autonomic signal is a skin resistivity signal, the detection can be partially based on the observation that some seizure types are associated with a deviation skin or body temperature from an interictal reference skin or body temperature value range (see for example, FIG. 4).

For example, certain partial seizures are associated with a decrease in skin resistivity (see for example, FIG. 6) and tonic-clonic seizures with an increase in body temperature.

In still another embodiment, when the neurologic signal is an eye signal, the detection can be partially based on the observation that some seizure types are associated with eye position changes (e.g., forced binocular deviation to the right) or the occurrence of abnormal eye movements (e.g., horizontal nystagmus) or both (see for example, FIG. 4). For example, absence seizures are associated with quasiperiodic blinking (see for example, FIG. 7).

The rate, amplitude and pattern of eyelid blinking may provide information about level of consciousness (e.g., awake vs. asleep or unresponsive) of a patient and during wakefulness. These parameters may allow for differentiation of normal vs. abnormal wakefulness states, e.g., abnormal wakeful state during complex partial and/or absence seizures, the state

following termination of complex partial and/or absence seizures, and/or the termination of generalized tonic clonic seizures. Parameters such as blinking rate, amplitude and inter-blinking interval (from which distinctive patterns may be discerned) may be used for detection and quantification of seizures as well as for classification purposes through comparisons with the non-seizure interictal state. Blinking activity, which is a form of kinetic activity, may be recorded using device(s) (e.g., electrodes) placed over or under the skin overlaying the supra- or infraorbital regions or with optical devices.

In one embodiment, when the autonomic signal is a blood signal, the detection can be partially based on the observation that some seizure types are associated with an increase in stress markers (e.g. catecholamines, cortisol, and metabolites thereof) relative to a reference level of the stress marker.

Should stress markers reach a prespecified reference value (which may be different than that used for detection of state change purposes), the patient's total antioxidant capacity and lipid peroxidation intensity may be monitored to institute neuroprotective measures, such as increasing total antioxidant capacity. Neuronal hyper-excitability which occurs in seizures may lead to excessive production of free radicals and eventually to neuronal injury.

Alternatively or in addition, the blood signal can be a blood gas (e.g., O₂ or CO₂) level or a blood pH level, and the detection can be partially based on the observation that some seizure types are associated with blood gas and/or pH levels outside of an interictal reference value range (see for example, FIG. 4). One or more of the blood signals described above may give information regarding respiratory signals, and vice versa.

For example, tonic-clonic seizures are associated with a drop in arterial O₂ concentration, an increase in arterial CO₂ concentration, and a decrease in blood pH (see for example, FIG. 5).

For another example, certain partial seizures are associated with a slight increase in arterial O₂ concentration, a decrease in arterial CO₂ concentration, and a slight increase in arterial pH (see for example, FIG. 6).

In one embodiment, when the neurologic signal is a brain signal, the detection can be partially based on the observation that some seizure types are associated with sudden, transient increases in the amplitude at certain frequencies of cortical waves or with changes in their morphology (e.g., spike-slow wave complexes) (see for example, FIG. 4).

In one embodiment, when the neurologic signal is a kinetic signal, the detection can be partially based on the observation that some seizure types are associated with increases or decreased in the amplitude and velocity of movements the appearance of particular patterns or sequences of body or appendicular movements, cessation of movements or loss of postural tone or marked increased in body muscle tone as provided by electromyography (EMG), accelerometer, inclinometer, and/or actigraph outputs (see for example, FIG. 4). EMG anti-gravitatory muscles provides similar information to accelerometers or inclinometers about falls and in certain cases, EMG may replace them. For example, if a patient is in the recumbent position and has a generalized tonic-clonic seizure, the inclinometer and the accelerometer will not detect a fall but the EMG will (indirectly) by showing absence of muscle activity in antigravitatory muscles. This also applies to patients that at the onset of the generalized tonic-clonic seizure are either propped/supported. Falls during certain generalized tonic clonic seizures are caused by increases not decreases in postural muscle tone. Also, while muscle tone may be decreased or increased during partial seizures,

the extent (number and type of muscle groups involved compared to generalized tonic-clonic seizures) allows for differentiation. Particular examples of kinetic signals relating to epileptic movements are shown in FIGS. 8-9.

U.S. Patent Application Publication 2009/0124870 to Arends et al. discloses a patient monitoring system using at least one heart rate sensor and a least one muscular tension sensor. The publication does not disclose acquisition or analysis of kinetic activity to monitor a patient. One or more of the embodiments of the present invention provide for detecting seizures through cardiac data (e.g., EKG) used in conjunction with motion data (e.g., accelerometer).

FIG. 8A shows a two-dimensional (x,y) discrete trajectory of epileptic movements (low sampling rate is used to minimize computations but a continuous trajectory may be plotted). This plot contains spatial (in reference to a fiducial marker such as the patient's sternum) and temporal information (when a movement occurs and their order of occurrence) about body movements during an epileptic seizure. The arrows show the sequence of movements. Colors or shapes, instead of arrows may be used to track the temporal evolution of movements. When stereotypical the movement trajectory may be used as a template for detection using for example matched filtering. This plot may be also generated in 3-D.

FIG. 8B shows a three-dimensional (x,y,z) discrete plot of epileptic movements. The movements form clusters (3 in this example; the left most and lower most clusters are intended to illustrate interictal movements and the right most cluster, epileptic movements) that may have different shapes or dimensions for each patient. These clusters may be used (e.g., cluster analysis, principal component analysis) for detection, quantification, classification and/or validation of detection of seizures, and optionally as well as for logging, tracking the temporal evolution of seizures, and/or optimization of detection, quantification, classification, and/or of therapy. This plot contains only spatial information; temporal information may be added through the use of arrow or color or shape codes. When stereotypical the movement trajectory may be used as a template for detection using for example matched filtering.

FIG. 8C shows a three-dimensional (x,y,z) discrete plot of epileptic movements; notice that one movement occurs only in 2-D (low sampling rate is used to minimize computations but a continuous trajectory may be recorded. This plot contains only spatial information (in reference to a fiducial marker such as the patient's sternum); temporal information may be added through the use of arrow or color or shape codes. When stereotypical the movement trajectory may be used as a template for detection using for example matched filtering.

FIG. 9 shows three two-dimensional, temporally cumulative plots of discrete movements during the clonic phase of a generalized (primarily or secondarily) tonic-clonic seizure. The first movement in the sequence is located closest to the x,y axes intersection and subsequent ones are plotted to the right of the preceding movement and in the order in which they occur. For ease of visualization there are 3 plots ((A) x,y; (B) y,z; (C) x,z). The vertical and horizontal axes provide information about amplitude and the horizontal axis also provides temporal information (e.g. inter-movement interval). In this illustration, the movements occur at equal time intervals and are periodic as is common in the clonic phase of a generalized seizure. When stereotypical the movement trajectory may be used as a template for detection using for example matched filtering.

U.S. Patent Application Publication 2009/0137921 to Kramer et al (Kramer) describes using accelerometer data to compare against previously stored motion data that are not

confined to epileptic events. One or more of the embodiments of the present invention provide for detecting seizures through cardiac data (e.g., EKG) used in conjunction with motion data (e.g., accelerometer). Embodiments of the present invention may provide for detecting seizures using less specific motion data since the cardiac and motion data may be used to confirm each other.

Herein, one or more of the direction, speed/acceleration, trajectory (1D to 3D), pattern, and quality of movement may be termed a characteristic of movement. Such characteristics of movement may be determined for particular movements and used to distinguish among ictal, post-ictal, and interictal motor activity.

For example, absence seizures are typically correlated with a cessation of body movements and temporary but complete loss of responsiveness and awareness (see for example, FIG. 7).

For another example, tonic-clonic seizures are associated with losses of responsiveness and awareness, and falls to the ground if the patient is standing at onset. Common characteristics of movement include a "spike" in the inclinometer's output at seizure onset (e.g., if the patient was standing, the seizure will cause him to fall), a quiet period of accelerometer output after seizure onset (e.g., the tonic phase), and a series of quasiperiodic "spikes" (e.g., at around 3 Hz) in accelerometer output after the tonic phase (e.g., the clonic phase), followed by cessation of body movements. The tonic phase presents with a marked increase in EMG activity in axial and appendicular muscles. Also, a "spike" in inclinometer output during or after the post-ictal phase may be seen (e.g., the patient rises after a fall at seizure onset) (see for example, FIG. 5).

For yet another example, certain partial seizures are often correlated with a quiet period of accelerometer output after seizure onset (see for example, FIG. 6), while others characterized by an increase in involuntary movements and vocalizations (e.g., so called "hypermotoric" seizures).

Generally, movement characteristics, qualities, and loci are similar, if not stereotypical, among tonic-clonic seizures and certain partial seizures for a particular patient, and are also similar among patients with these seizure types. Thus, patterns can often be obtained and used for detection, quantification, and classification. However, in certain partial seizures, movements may differ not only between patients but also between seizures of the same patient.

In some embodiments of this invention, the number, type, and placement of motion sensors to be used in detecting, quantifying, and/or classifying movement can be based on (a) degree of movement similarity between seizures, (b) the signal-to-noise ratio of data from the locus or loci (e.g., body parts such as eyes, head, limbs, trunk, etc.), and/or (c) patient safety and device longevity considerations, among others. These considerations can be taken into account to maximize speed and/or accuracy of detection, quantification, and/or classifying, and/or performing this task or tasks in a monetary and/or computationally cost-effective manner.

For example, if a patient's tonic-clonic seizures are consistently preceded by a deviation of the head to the right, a single motion sensor (e.g., placed in this case on the head or over/in a neck muscle involved in the movement) may be sufficient to detect the motion and characterize the seizure. If the patient's seizures are characterized by sudden falls, again, a single device, placed in a body part that will have most acceleration or range of displacement, may be sufficient for seizure detection, quantification and classification purposes. If the patient's seizures are frequently secondarily generalized seizures, a plurality of devices, with at least one situated

on each of the left and right sides of the body and/or with at least one situated on the upper and lower portions of the body may be desirable to provide sufficient sensitivity and specificity for seizure detection and characterization.

The choice of number of sensors, their type (e.g., whether they are sensitive to mechanical or electrical signal changes), and their placement can be optimized for each seizure type and patient.

In one embodiment, when the neurologic signal is a brain signal, the detection can be partially based on the observation that some seizure types are typically correlated with a decrease in responsiveness (see for example, FIG. 4).

For yet another example, partial seizures can often be distinguished between simple and complex based on changes in the patient's responsiveness. Simple partial seizures are associated with preservation of awareness and memory for the events that occurred during the seizure and responsiveness may or may not be preserved, whereas complex partial seizures are invariably characterized by impairment in the patient's unawareness of their surroundings and anterograde amnesia spanning a certain time period (see for example, FIG. 6). Responsiveness is tested by having the patient perform certain motor actions (e.g., press a button; raise an arm) and/or cognitive tasks (e.g., answer questions). Awareness may be tested by measuring a patient's ability to recollect events that occurred during a certain period of time or by administering memory tests. The number of words, images or events correctly recalled allow quantification of the degree of awareness (compared to an inter-ictal reference value). In one embodiment, the method further comprises providing a responsiveness test and awareness tests to assess patient's responsiveness and awareness, and characterizing the epileptic event based upon the speed and appropriateness or correctness of the responses to neuropsychologic tests.

For example, the following table shows conclusions that can generally be drawn from determinations of whether a patient remains responsive ("Responsive?") and/or remains aware ("Aware?") during a seizure.

Responsive?	Aware?	Reasonable conclusion
Yes	Yes	Not a complex partial or secondarily generalized seizure
Yes or No	No	Complex partial seizure
No	Yes	Simple partial seizure interfering with ability to respond
No	No	Complex partial or primarily or secondarily generalized seizure

The autonomic signal and the neurologic signal can be used to detect a seizure; to quantify its severity; to classify a seizure as to its type (e.g., absence, tonic-clonic, simple partial, complex partial); and/or to validate an identification or detection of a change of state as corresponding to a seizure.

The features of the two or more signals on which a detection or other action of the present invention is based may occur simultaneously or in any temporal relationship. In one embodiment, the temporal relationship between two signals is as set forth in FIGS. 4-7 and as described above. Relative temporal relationships between the body signals may be used to identify, validate, classify, and/or quantify an epileptic event. Information relating to the timing of any two body signals, e.g., an increase in heart rate before, after, or substantially simultaneously with accelerometer data suggestive of a seizure, may be used to identify an epileptic event, validate an

identification of an epileptic event, quantify an epileptic event's severity, intensity, or duration, and/or classify a seizure.

The various embodiments recited above may be also used to distinguish epileptic generalized from non-epileptic generalized seizures whose kinetic activity, but not patho-physiology, resembles that of epileptic seizures. Non-epileptic generalized seizures, also known as pseudo-seizures, psychogenic seizures, or hysterical seizures, are often misdiagnosed as epileptic at large cost to the patient, caregivers, and the health care system. A multimodal signal approach relying heavily on kinetic, autonomic and metabolic signals is ideally suited for diagnosing identifying and classifying seizures as non-epileptic given its high sensitivity and specificity and cost-effective (no hospital admission would be required as this invention's methods are implementable in small portable devices).

The following are a few examples of differences with high discriminatory values, one or more of which can be used to distinguish between epileptic generalized seizures and non-epileptic generalized seizures: a) The intensity of non-epileptic movements, unlike that of epileptic movements, waxes and wanes (crescendo-decrescendo pattern) throughout the event; b) Non-epileptic movements, unlike epileptic movements, are multi-directional or multi-planar, said changes in direction occurring very rapidly and in a random sequence. For example, vertical movements may give way to horizontal ones and these in turn to oblique or rotary or flapping movements; c) Joint movements in non-epileptic seizures, unlike in epileptic seizures, are incoherent or disorganized: while the right upper extremity is moving in the vertical plane at a certain speed and with certain amplitude and phase, the direction, speed, phase and amplitude of movement of the left upper extremity may be different at the same time; d) in non-epileptic seizures, unlike in epileptic seizures, co-activation of agonists and antagonists muscle groups is rarely seen: Co-activation of the abdominal and paraspinal muscles during an epileptic generalized tonic-clonic seizure keeps the torso straight while the sole activation of paraspinal muscles, a common observable in non-epileptic generalized seizures, manifests as an arched back; e) Involvement (in the form of movements) of certain body parts is commonly found in non-epileptic seizures while they are rarely if ever seen in epileptic generalized seizures; pelvic thrust, pelvic gyrations, and other pelvic movements are nearly pathognomic of non-epileptic seizures; f) Metabolic (lactic) acidosis occurs with epileptic generalized tonic-clonic seizures and not with non-epileptic generalized seizures.

Detection can be conducted by any appropriate technique. For example, each signal may be recorded, conditioned, and processed using hardware (e.g., DC or AC amplifiers), gains or amplification, filters and sampling rates appropriate for the spectral properties, and/or time-scale and characteristics of each signal. Each signal may be analyzed whole or after decomposition using suitable digital or analog signal processing techniques. The decomposition may be performed using any of the following techniques: Fourier transform based methods, wavelets, customized FIR or IIR filters, intrinsic time scale decomposition, wavelet transform maximum modulus, or any other technique which may decompose the signal based on its spectral properties, morphology or waveform, site of origin or generation, its position regarding a baseline, zero-crossings and circadian or ultradian rhythms. In the case of a decomposed signal none, one, or more of the components may be discarded if it is deemed of little value for detection of change of brain/body state. These data, as they stream through the system, may be analyzed in windows of

appropriate length for each signal (e.g., signal-based customized window approach). This window corresponds to a foreground which may be referenced for quantitative purposes to a background, consisting of past data. The length of the background window may be determined by the properties of the signal under study and the time scale of the patterns or events which are the subject of detection. Any of these features or parameters may be adapted as needed to account for circadian or other influences to the signals

Although the above paragraph emphasizes hardware for signal conditioning and other tasks, the person of ordinary skill in the art is aware that software, firmware, or other implementations of one or more of the techniques discussed above may be used.

Change in a given signal feature may be associated with one, more than one or none of the brain/body state changes of interest. Reciprocally, changes in brain state may be associated with only one signal feature change, two or more, or none. Each signal feature may be tracked individually and its changes may be subjected to statistical, cluster, Poincaré plot, and/or other forms of analyses to identify changes which are significantly correlated with pathological brain/body state changes such as seizures, movement disorders or with physiological ones such as sleep, attention or cognitive processes. These analyses may yield selectivity (SI), sensitivity (Se) and specificity (Sp) for each signal feature and may be used to assign values to each of them. The type/number of signal feature used for on-line, real-time detection of changes in brain/body state may be chosen using a value system based on the degree of selectivity (SI), sensitivity (Se) and specificity (Sp) of each signal feature.

Selectivity is given by the fraction or proportion of type of state changes with which a signal feature is associated. For example, if a state change is associated with only one signal feature change the selectivity would be 1 (1/1) or if it is associated with 2, selectivity would be 0.5 (1/2).

Sensitivity is given by the fraction of detected changes in signal feature over all detectable changes in signal features; for example, if there are 20 state changes/day and 10 of these are detected using a certain signal feature, sensitivity for this signal feature in this case would be 0.5 (10/20).

Specificity is given by the fraction of detected true changes over all detections; for example, if there were 20 detections using a certain signal feature but only 10 corresponded to true brain/body state changes, the signal feature's specificity would be 0.5 (10/20).

The value (for detection purposes) of each signal feature for a particular brain or body state (e.g., ictal, pre-ictal, post-ictal, or interictal, among others) (f) is the product of selectivity (SI), sensitivity (Se) and specificity (Sp); $f = SI \times Se \times Sp$. The closer the value to 1 (which is the maximum possible), the more powerful the signal feature may be considered to be. This value, f, may determine the number of signal features necessary to maximize the probability of accurate and reliable detection of brain/body change of state: Any signal feature with a value of 1 may be used as the only detection signal feature. Signal features with value $f < 1$ may be sorted out, ranked, and added to obtain a summed weighted index F, $(F = fEKG + fEOG + \dots + fTT)$. F may be calculated in real-time, if the computations required can be performed at an acceptable power expense, or off-line if this is not the case. For example, if data analysis in a certain subject reveals that seizures are accompanied by acceleration in heart rate and this change has selectivity, sensitivity and specificity of 1 so that $fEKG = 1$, this signal feature may be chosen as the only one for automated detection purposes. However, if $fEKG < 1$, other f values, as many as needed or desired, may be added, to

reach or approach a desirable high value, such as 1, if the computations can be performed in real-time at an acceptable power cost.

For a particular example, consider a situation where the signal feature values are [$fEOG = 0.40$; $fEKG = 0.45$; $fPKG = 0.10$; $fSkT = 0.15$; $fEMG = 0.12$; $fAt = 0.14$; $fTT = 0.09$]; these values are sorted out and ranked from highest to lowest [$fEKG = 0.45$; $fEOG = 0.40$; $fSkT = 0.15$; $fAt = 0.14$; $fEMG = 0.12$; $fPKG = 0.10$; $fTT = 0.09$] and as many values as needed are added to obtain $F = 1$ (e.g., in this case, $F = 0.45 + 0.40 + 0.15 = 1$; in this case 3 values sufficed to reach 1. It should be noted that in certain cases, addition of all indices may not equal 1, in which case detection of state changes may be issued if and when F is greater than a lower number, such as 0.5. Threshold (T), duration (t) other constraints (such as time of day or patient's state (awake vs. asleep; resting wakefulness vs. exercise) may be introduced to improve accuracy of detection, if desired.

Another metric of interest is the property defined herein as degree of signal ubiquitousness (U) denoting the number of different states during which the same signal feature changes. For example, cardiac activity is highly ubiquitous since increase in heart rate occur during different normal (exercise, emotion) and abnormal states (seizures, cardiac arrhythmias), while metabolic (lactic) acidosis would be absent from all, save only generalized tonic-clonic seizures and in extreme/endurance exercise, a rare practice. Ubiquitousness (U) is the fraction of a signal feature present in various states over the total number of states. The ubiquitousness (U) of heart rate in the example above, is 1 since it occurs in 4/4 states while that of lactic acidosis is 0/4 or at most 1/4 if extreme exercise is included. U may replace SI in the calculation of F to optimize performance of state detection changes. While in certain cases U is the reciprocal of SI. There may be certain cases in this relation does not apply and U maybe more useful. As stated, in one embodiment, detecting the epileptic event is based on an autonomic signal and a neurologic signal. In one embodiment, an algorithm can receive as inputs both the autonomic signal and the neurologic signal and process them together to yield an output indicative of a detection or a non-detection. In another embodiment, detecting the epileptic event comprises identifying a putative epileptic event based on one of the autonomic signals (e.g., cardiac signals as measured by EKG) and one of the neurologic signals (e.g., kinetic signals as measured with an accelerometer, an inclinometer, or an actigraph), and validating the identifying based on one of the other of the autonomic signals (e.g., respiration) and one of the other neurologic signal (e.g., responsiveness test, memory test, comprehension tests, etc.).

Another metric of interest is Positive Predictive Value (PPV), defined as:

$$\frac{\text{(number of True Positives)}}{\text{(number of True Positives + number of False Positives)}}$$

Regardless how the detection is made, in one particular embodiment, the present invention relates to a method for detecting an epileptic event based upon a patient's cardiac signal and kinetic activity, comprising providing a cardiac signal indicative of the patient's heart beats; providing a kinetic signal indicative of a body movement of the patient; and detecting an epileptic event based upon the cardiac signal and the kinetic signal.

The cardiac signal may be electrical, acoustic, thermal, or any other cardiac signal detectable using certain equipment or tools. In one embodiment, the cardiac signal is provided by an electrocardiogram (EKG).

The kinetic signal can be provided by a device capable of recording any of the attributes inherent to movement such as amplitude, velocity, direction, trajectory and quality. In one embodiment, the kinetic signal is provided by an accelerometer, an inclinometer, or an actigraphic device. An actigraphic device or actigraph can be considered as being both an accelerometer and an inclinometer. An exemplary plot of trajectories is shown in FIG. 8A. An exemplary plot of clusters of positions is shown in FIG. 8B.

In one embodiment, the present invention relates to a method for detecting an epileptic event based upon a patient's cardiac signal and kinetic activity, comprising providing a kinetic signal indicative of a body movement of the patient; calculating based on the kinetic signal a kinetic score indicative of a correlation of said kinetic signal with an epileptic event; detecting an epileptic event based upon the patient's heart beat sequence; and providing an output indicative of an epileptic event based on the kinetic score.

In another embodiment, the method comprises providing a cardiac signal indicative of a cardiac activity of the patient; calculating based on the cardiac signal a cardiac score indicative of a correlation of said cardiac signal with an epileptic event; detecting an epileptic event based upon the patient's kinetic activity; and providing an output indicative of an epileptic event based on the cardiac score.

These are both examples of detecting an epileptic event based upon multimodal data, using a plurality of modes of data (e.g., a cardiac mode signal and a kinetic mode signal).

The kinetic signal indicative of a body movement of the patient can be as described above. A kinetic score can be calculated and/or the kinetic signal can be classified as either an epileptic event kinetic signal or a non-epileptic event kinetic signal based on the practitioner's knowledge (e.g., the practitioner is aware certain kinetic signals, e.g., inclinometer spikes, periods of increased accelerometer activity, periods of decreased accelerometer activity, periods of actigraph activity outside of normal ranges, timewise correlations of such signals, etc.), by prior correlation of a patient's kinetic signals with his or her seizures identified by autonomic (e.g., EKG), neurologic (e.g., EEG or direct or indirect clinical observation) endocrine, metabolic (e.g., pH), stress marker (e.g., cortisol) etc., or a combination thereof.

Imaging (e.g., video, thermography, etc.) and/or audio recordings of the patient may be used qualitatively or quantitatively to detect and/or validate the detection of seizures. Detection or validation may be made on- or off-line via human visual analysis or using algorithms that compare one or more of position, velocity, direction, or trajectory of movement of any body part during seizures to non-seizure movements. The time between consecutive movements, the total duration of epileptic movements, and/or their quality (e.g., jerky or smooth) may be also used for detection and/or validation of seizures.

Detecting a possibility of an epileptic event based upon the patient's heart beat sequence can make use of the cardiac-based seizure detection approaches discussed above. For example, noting an increase in the patient's heart rate relative to an interictal reference value is one embodiment of "detecting an epileptic event," e.g., a period of increased likelihood of a seizure.

Upon classifying the kinetic signal and detecting the possibility of the epileptic event based upon the patient's heart beat sequence, an output indicative of an epileptic event can be provided if the kinetic signal is classified as an epileptic event kinetic signal; and an output indicative of the non-occurrence of an epileptic event can be provided if the kinetic

signal is classified as a nonepileptic event kinetic signal. This method can validate a cardiac-based seizure detection by use of kinetic signals.

In another embodiment, the present invention relates to a method for detecting an epileptic event based upon a patient's cardiac signal and kinetic activity, comprising providing a kinetic signal indicative of a body movement of the patient; classifying the kinetic signal as either an epileptic event kinetic signal or a nonepileptic event kinetic signal; detecting an epileptic event based upon changes in the patient's heart beat sequence; confirming the detecting if said kinetic signal is classified as an epileptic event kinetic signal; overriding the detecting if said kinetic signal is classified as a nonepileptic event kinetic signal; and providing an output indicative of an epileptic event only if the detecting is confirmed.

In yet another embodiment, the present invention relates to a method for detecting a tonic-clonic epileptic seizure whether primarily or secondarily generalized (i.e., whether the seizure emerges in both hemispheres of the brain at substantially the same time (primary) or whether it emerges at a particular focus and then spreads (secondary) based upon two or more of a patient's body signals, comprising: providing at least two body signals selected from the group consisting of a cardiac signal indicative of the patient's heart beats; an accelerometer signal indicative of the patient's movement; an inclinometer signal indicative of the patient's body position; an actigraph signal indicative of the patient's movement, body position, or both; a respiratory signal indicative of the patient's respiration; a skin resistivity signal indicative of the patient's skin resistivity; an blood gas signal indicative of the patient's blood oxygen content, carbon dioxide content, or both; a blood pH signal indicative of the patient's blood pH; an isometric force signal indicative of the patient's muscle activity; a sound signal indicative of the patient's oral utterances or vocalizations; an ocular signal indicative of the patient's eye position and movements; a responsiveness signal indicative of the patient's responsiveness; and a stress marker signal indicative of at least one stress marker of the patient; and detecting the generalized tonic-clonic epileptic seizure based upon the timewise correlation of two features, one feature being of each of the at least two body signals, wherein:

the feature of the cardiac signal is an increase in the patient's heart rate above a reference value;

the feature of the accelerometer signal is an increase in the velocity, amplitude or number of movements per unit time of said patient above a reference value followed by a decrease in the patient's movement below a reference value;

the feature of the inclinometer signal is a rapid change of the patient's body position indicative of a fall;

the feature of the respiratory signal is a brief apnea followed by hypopnea and after the end of the seizure by a transient increase in respiratory rate, tidal volume, and minute volume;

the feature of the skin resistivity signal is a skin resistivity outside an interictal reference value range;

the feature of the blood gas signal is a decrease in the patient's arterial blood oxygen content below an interictal reference value and an increase in arterial carbon dioxide content above an interictal reference value, or both;

the feature of the blood pH signal is a decrease in the patient's blood pH below an interictal reference value;

the feature of the isometric force signal or EMG activity is a transient increase in the patient's muscle contractions above an interictal reference value that may be preceded or followed

depending on the seizure type (e.g., primarily vs. secondarily generalized) and patient by a loss of muscle tone or of EMG in anti-gravitatory muscles

the feature of the sound signal is a distinctive sound referred to as a patient's an "epileptic cry";

the feature of the ocular signal is a deviation of the patient's eye's often upwardly;

the feature of the responsiveness signal is a decrease in the patient's responsiveness below an interictal reference value;

and the feature of the stress marker signal is an increase in at least one stress marker of the patient above an interictal reference value.

In one embodiment, this method further comprises indicating the end of the generalized tonic-clonic epileptic seizure when the value of one or more of the features listed above falls outside the range of values for both the ictal and inter-ictal states for that patient.

Alternatively or in addition, in one embodiment, this method further comprises indicating the beginning of a post-ictal period based upon the appearance of at least one post-ictal feature of at least one said body signal, wherein:

the post-ictal feature of the cardiac signal (e.g. heart rate) is outside the range of values for the ictal and interictal periods for that patient and within the range of postictal values;

the post-ictal feature of the accelerometer signal is a cessation of the patient's seizure movements; the post-ictal feature of the respiratory signal is a transient increase in the patient's respiratory frequency, tidal volume, and/or minute volume, such as may follow periods of apnea and hypopnea and the patient's seizure movements; and

the post-ictal feature of the responsiveness and of the awareness signal is the persistence in the patient's unresponsiveness and unawareness. As should be apparent, "unresponsiveness" and "unawareness" are distinct phenomena; a person may be aware of stimuli (and able to form memories of said stimuli and the context in which they occurred) but unable to respond thereto, and vice versa. Responsiveness as used herein refers to the ability to respond reflexively or adaptive/purposefully; this distinction may be used for seizure classification purposes.

The term "post-ictal," is not necessarily limited to the period of time immediately after the end of the primarily or secondarily generalized tonic-clonic epileptic seizure and is not limited to this type of seizure but also encompasses partial seizures (e.g., all complex and certain simple partial and absence seizures). Rather, it refers to the period of time during which at least one signal has one or more features associated with the period following the cessation of a seizures that indicates one or more of the patient's body systems are not functioning normally (e.g., as a result of the seizure or of an injury suffered during the seizure) but are not exhibiting features indicative of a seizure.

In a further embodiment, this method further comprises indicating the end of the post-ictal period and the beginning of the inter-ictal period when the values of at least one of the post-ictal features changes to being within the range of reference body signal values or behavior associated only with the inter-ictal period wherein:

the cardiac signal returns to a heart rate within a range indicative of an interictal state for said patient

the accelerometer signal of the patient's movement velocity, amplitude or number of movements per unit time returns to values indicative of an inter-ictal state for said patient;

the accelerometer signal is a movement pattern including inter-movement intervals or trajectory indicative of that patient's inter-ictal period

the respiratory signal (e.g., rate, tidal volume, minute volume, and pattern) returns to a range indicative of the inter-ictal state for that patient; the responsiveness signal returns to its range of inter-ictal values for that patient; and

the patient's awareness returns to inter-ictal ranges for the patient.

The changes in signal features (e.g., responsiveness, awareness, heart activity, respiratory activity, etc.) during the transitions (e.g., inter-ictal to ictal, ictal to post-ictal and post-ictal to interictal) that make up the epileptic cycle, may or may not occur simultaneously or synchronously; certain signal feature values change ahead or behind others. Thus, using these signal features, the transitions may be qualitatively classified into (a) partial or complete; (b) quantitatively as the fraction of signal features (numerator) that transitioned into or out of the state over the total number of signal features that have been observed (denominator).

For example, if only 2/4 signal feature values indicative of the transition from ictal to postictal or from post-ictal to inter-ictal have reached values within the range of the new state, the is classified as partial assigned an score of 0.5 and declared complete only when all (e.g., 4/4 in this example) signal features values are within the range of indicative of the new state at which time the transition is deemed completed.

The transitions may be also quantified using the: a) magnitude of the change in feature signal values measured for example as the increase in seizure energy (see Osorio et al, *Epilepsia* 1998, 2001) as compared to its inter-ictal value, or the percent of incorrect responses to a complex reaction time test compared to the responses in the inter-ictal state, or the lengthening in response time regardless of correctness of responses (see, e.g., U.S. Ser. No. 12/756,065, filed Apr. 7, 2010, which is hereby incorporated herein by reference) compared to that recorded in the inter-ictal state for that patient; b) rate of change in the signal features measured for example as the time to peak value change measured from the onset time of the transition or the time to first error in a complex reaction time compared to those obtained in the inter-ictal period; c) duration (e.g., in seconds) of the state change from the onset of the inter-state transition to the beginning of the transition from the present state (e.g., ictal) to another state (e.g. post-ictal). These metrics may be used to e.g., assess the disease state (e.g., the duration and magnitude of the ictal state are increasing over time) and also the efficacy of therapeutic interventions. Shortening the magnitude of the changes (e.g., degree of unresponsiveness) in signal feature values from the inter-ictal range to the ictal value or the transition time between the post-ictal and interictal periods provide evidence that the therapy is beneficial while increases in the magnitude or duration of the changes in feature signals from the inter-ictal range to ictal value or a lengthening of the transition from the post-ictal to the interictal state are evidence of an adverse therapeutic effect. The qualitative and quantitative categorization of the various states and of their transitions is applicable to all seizures and epilepsy types and also to other states and inter-state transitions.

Analogously to detecting tonic-clonic seizures, in one embodiment, the present invention relates to a method for detecting a partial epileptic seizure based upon two or more of a patient's body signals, comprising providing at least two body signals selected from the group consisting of a cardiac signal indicative of the patient's heart beats; an accelerometer signal indicative of the patient's movement; an inclinometer signal indicative of the patient's body position; an actigraph signal indicative of the patient's movement, body position, or both; a respiratory signal indicative of the patient's respiration; a skin resistivity signal indicative of the patient's skin

resistivity; an arterial blood gas signal indicative of the patient's blood oxygen content, carbon dioxide content, or both; an arterial blood pH signal indicative of the patient's blood pH; a sound signal indicative of the patient's oral utterances or vocalizations or breathing; a responsiveness signal indicative of the patient's responsiveness; an endocrine signal indicative of seizures and a stress marker signal indicative of the occurrence of tissue stress; and detecting the partial epileptic seizure based upon the timewise correlation of two features, one feature being of each of the at least two body signals, wherein:

the feature of the cardiac signal is a patient's heart rate outside an interictal reference value range;

the feature of the accelerometer signal is a movement outside an interictal reference value range;

the feature of the respiratory signal is a respiration rate, tidal volume, and/or minute volume outside an interictal reference value range;

the feature of the skin resistivity signal is a skin resistivity outside an interictal reference value range;

the feature of the arterial blood gas signal is an arterial blood oxygen content outside an interictal reference value range, an arterial carbon dioxide content outside an interictal reference value range, or both;

the feature of the blood pH signal is a blood pH outside an interictal reference value range;

the feature of the sound signal is a change in the patient's oral utterances or vocalizations outside an interictal reference value range;

and the feature of the stress marker signal is an increase in the patient's endocrine or stress markers above an interictal reference value.

Partial seizures can be distinguished from generalized seizures. Partial seizures that evolve into secondarily generalized seizures can also be distinguished from primarily generalized seizures. Also, within the class of partial seizures, simple partial seizures can be distinguished from complex partial seizures.

In a further embodiment, this method further comprises classifying the partial epileptic seizure as a complex partial seizure if a feature of the awareness signal timewise correlated with the at least one body signals is a decrease in the patient's awareness or other cognitive functions below an interictal reference value, and as a simple partial seizure if the patient's awareness or other cognitive function remain at or above an inter-ictal reference a feature of the awareness signal timewise correlated with the at least two body signals.

Alternatively or in addition, in one embodiment, the method further comprises indicating the end of the partial epileptic seizure when at least one of the signal features the respective body signal is outside the range of values for the ictal and interictal periods for that patient and within the range of postictal values;

Alternatively or in addition, in one embodiment, the method further comprises indicating the beginning of a post-ictal period based upon the appearance of at least one post-ictal feature of at least one said body signal, wherein:

the cardiac signal is a heart rate outside an ictal reference value range and within a range indicative of a post-ictal state for said patient;

the accelerometer signal is a movement velocity, amplitude, or number of movements per unit time outside an ictal reference range of values and within a range indicative of a post-ictal state for said patient;

the accelerometer signal is a movement pattern, trajectory, or inter-movement intervals outside an ictal reference value range and within a range indicative of a post-ictal state for said patient;

the respiratory signal is a respiration rate outside the ictal range of values for that patient and within a post-ictal range for said patient;

the responsiveness signal is a change in the patient's unawareness or cognitive dysfunction to a value outside both of an ictal range and an interictal range; and

the awareness signal is a change in the patient's awareness to a value outside both an ictal range and an interictal range.

In a further embodiment, the method further comprises indicating the end of the post-ictal period when each of the features from the respective body signal returns to the range of values associated with the interictal period.

Alternatively or in addition, in one embodiment, the method further comprises indicating the beginning of the inter-ictal period based upon the appearance of at least one inter-ictal feature of at least two said body signal, wherein:

the inter-ictal feature of the cardiac signal is a return of the patient's heart rate values to inter-ictal reference values and outside a range indicative of a post-ictal and ictal state for said patient;

the inter-ictal feature of the accelerometer signal is a return of the patient's movement velocities, amplitudes, or number of movements per unit time to the inter-ictal value range for that patient and outside the values or patterns indicative of a post-ictal and ictal states;

the inter-ictal feature of the accelerometer signal is a return of the movement patterns or trajectories to those present in the inter-ictal period for that patient and different from those present during the post-ictal and ictal states;

the inter-ictal feature of the respiratory signal is return of the respiratory frequency to inter-ictal values for that patient and outside those indicative of post-ictal and ictal states;

the inter-ictal feature of the responsiveness signal is a return of the patient's responsiveness to a range of values seen in the inter-ictal state for that patient and outside a range of values indicative of post-ictal and/or ictal states

the inter-ictal feature of the awareness signal is a return of the patient's awareness to a range of values seen in the inter-ictal state for the patient and outside a range of values indicative of post-ictal and/or ictal states.

Regardless of how an epileptic event is detected, in some embodiments, a responsive action may be taken selected from warning, logging the time of an epileptic event, computing and storing one or more seizure severity indices, or delivering a therapy to prevent, abate or lessen the severity of the ictal or postictal states. Further responsive actions such as warning, logging and treatment may be taken if the ictal or postictal states severity exceeds for example the 90th percentile values for a patient.

A warning may be given as, for example, a warning tone or light implemented by a medical device or a device adapted to receive indications of the seizure; as an automated email, text message, telephone call, or video message sent from a medical device or a unit in communication with a medical device to the patient's cellular telephone, PDA, computer, television, 911 or another emergency contact number for paramedic/EMT services, etc. Such a warning may allow the patient or his or her caregivers to take measures protective of patient's well-being and those of others, e.g., pulling out of traffic and turning off a car, when the patient is driving; stopping the use of machinery, contacting another adult if the patient is providing childcare, removing the patient from a swimming pool or bathtub, lying down or sitting if the patient is standing, etc.

The time may be logged by receiving an indication of the current time and associating the indication of the current time with an indication of the epileptic event.

Seizure severity indices may be calculated and stored by appropriate techniques and apparatus.

A seizure may be treated by appropriate techniques, such as those discussed below. The treatment may be one or more treatments known in the art. In one embodiment, the treatment comprises at least one of applying an electrical signal to a neural structure of a patient; delivering a drug to a patient; or cooling a neural structure of a patient. When the treatment comprises applying an electrical signal to a portion of a neural structure of a patient, the neural structure may be at least one of a portion of a brain structure of the patient, a portion of a cranial nerve of a patient, a portion of a spinal cord of a patient, a portion of a sympathetic nerve structure of the patient, a portion of a parasympathetic nerve structure of the patient, and/or a portion of a peripheral nerve of the patient.

Though not intended to be bound by theory, in certain circumstances, an epileptic event may be identified at a time before event onset would be determined by electroencephalography, observation by a physician or knowledgeable layman, or both. The time before onset may range from a few seconds up to a few minutes. As such, certain embodiments of the method may be considered to yield a prediction of an epileptic event. It should be noted that the prediction may sometimes be a false positive. However, depending on a physician's judgment, his or her understanding of the devices in use, and the patient's condition, a certain amount of false positives may be tolerable.

Even if no prediction is made, i.e., the methods of various embodiments of this invention are capable of identifying an epileptic event at or after the time of electrographic onset, such information may be useful for identifying an epileptic event without the need for EEG monitoring, implanted sensors, or clinical observation, and with a higher signal-to-noise ratio than EEG monitoring using scalp electrodes. Even though scalp recordings are the most common modality for seizure detection, this modality has low sensitivity (e.g., a large number of epileptic seizures are not accompanied by electrical changes at the scalp), low specificity (e.g., muscle and movement artifacts may resemble electrical seizure activity at the scalp), and also may have long latency between the emergence of epileptic activity in certain brain regions and the appearance, if any, of electrical activity at the scalp.

EEG, implanted sensors, and clinical monitoring or observation often have low signal-to-noise ratios, sensitivity and specificity. These modalities are often disruptive of the patient's normal life, and can generally only be used for limited time periods due to the risk of infection and other injury. These undesirable limitations can generally be avoided in some embodiments of the present method.

Also, the method can make use of multiple modalities of data, thus providing a method of identifying epileptic seizures that may provide greater selectivity, sensitivity, and/or specificity. The information is also useful for identifying an epileptic event with greater accuracy than is generally exhibited by seizure diaries. Surprisingly, seizure diaries kept by the patient are often highly inaccurate with numerous false negatives.

Although not limited to the following, an exemplary system capable of implementing embodiments of the present invention is described below. FIG. 1 depicts a stylized implantable medical system (IMD) 100 for implementing one or more embodiments of the present invention. An electrical signal generator 110 is provided, having a main body 112 comprising a case or shell with a header 116 for connecting to

an insulated, electrically conductive lead assembly 122. The generator 110 is implanted in the patient's chest in a pocket or cavity formed by the implanting surgeon just below the skin (indicated by a dotted line 145), similar to the implantation procedure for a pacemaker pulse generator.

A nerve electrode assembly 125, preferably comprising a plurality of electrodes having at least an electrode pair, is conductively connected to the distal end of the lead assembly 122, which preferably comprises a plurality of lead wires (e.g., one wire for each electrode). Each electrode in the electrode assembly 125 may operate independently or alternatively, may operate in conjunction with the other electrodes. In one embodiment, the electrode assembly 125 comprises at least a cathode and an anode. In another embodiment, the electrode assembly comprises one or more unipolar electrodes.

Lead assembly 122 is attached at its proximal end to connectors on the header 116 of generator 110. The electrode assembly 125 may be surgically coupled to the vagus nerve 127 in the patient's neck or at another location, e.g., near the patient's diaphragm or at the esophagus/stomach junction. Other (or additional) cranial nerves such as the trigeminal and/or glossopharyngeal nerves may also be used to deliver the electrical signal in particular alternative embodiments. In one embodiment, the electrode assembly 125 comprises a bipolar stimulating electrode pair 126, 128 (i.e., a cathode and an anode). Suitable electrode assemblies are available from Cyberonics, Inc., Houston, Tex., USA as the Model 302 electrode assembly. However, persons of skill in the art will appreciate that many electrode designs could be used in the present invention. In one embodiment, the two electrodes are wrapped about the vagus nerve, and the electrode assembly 125 may be secured to the vagus nerve 127 by a spiral anchoring tether 130 such as that disclosed in U.S. Pat. No. 4,979, 511 issued Dec. 25, 1990 to Reese S. Terry, Jr. Lead assembly 122 may be secured, while retaining the ability to flex with movement of the chest and neck, by a suture connection to nearby tissue (not shown).

In alternative embodiments, the electrode assembly 125 may comprise temperature sensing elements, blood pressure sensing elements, and/or heart rate sensor elements. Other sensors for other body parameters may also be employed. Both passive and active stimulation may be combined or delivered by a single IMD according to the present invention. Either or both modes may be appropriate to treat a specific patient under observation.

The electrical pulse generator 110 may be programmed with an external device (ED) such as computer 150 using programming software known in the art. A programming wand 155 may be coupled to the computer 150 as part of the ED to facilitate radio frequency (RF) communication between the computer 150 and the pulse generator 110. The programming wand 155 and computer 150 permit non-invasive communication with the generator 110 after the latter is implanted. In systems where the computer 150 uses one or more channels in the Medical Implant Communications Service (MICS) bandwidths, the programming wand 155 may be omitted to permit more convenient communication directly between the computer 150 and the pulse generator 110.

Turning now to FIG. 2, a block diagram depiction of a medical device 200 is provided, in accordance with one illustrative embodiment of the present invention. In some embodiments, the medical device 200 may be implantable (such as implantable electrical signal generator 110 from FIG. 1), while in other embodiments the medical device 200 may be completely external to the body of the patient.

The medical device **200** may comprise a controller **210** capable of controlling various aspects of the operation of the medical device **200**. The controller **210** is capable of receiving internal data or external data, and in one embodiment, is capable of causing a stimulation unit (not shown) to generate and deliver an electrical signal, a drug, cooling, or two or more thereof to one or more target tissues of the patient's body for treating a medical condition. For example, the controller **210** may receive manual instructions from an operator externally, or may cause an electrical signal to be generated and delivered based on internal calculations and programming. In other embodiments, the medical device **200** does not comprise a stimulation unit. In either embodiment, the controller **210** is capable of affecting substantially all functions of the medical device **200**.

The controller **210** may comprise various components, such as a processor **215**, a memory **217**, etc. The processor **215** may comprise one or more microcontrollers, microprocessors, etc., capable of performing various executions of software components. The memory **217** may comprise various memory portions where a number of types of data (e.g., internal data, external data instructions, software codes, status data, diagnostic data, etc.) may be stored. The memory **217** may comprise one or more of random access memory (RAM), dynamic random access memory (DRAM), electrically erasable programmable read-only memory (EEPROM), flash memory, etc.

The medical device **200** may also comprise a power supply **230**. The power supply **230** may comprise a battery, voltage regulators, capacitors, etc., to provide power for the operation of the medical device **200**, including delivering the therapeutic electrical signal. The power supply **230** comprises a power source that in some embodiments may be rechargeable. In other embodiments, a non-rechargeable power source may be used. The power supply **230** provides power for the operation of the medical device **200**, including electronic operations and the electrical signal generation and delivery functions. The power supply **230** may comprise a lithium/thionyl chloride cell or a lithium/carbon monofluoride (LiCFx) cell if the medical device **200** is implantable, or may comprise conventional watch or 9V batteries for external (i.e., non-implantable) embodiments. Other battery types known in the art of medical devices may also be used.

The medical device **200** may also comprise a communication unit **260** capable of facilitating communications between the medical device **200** and various devices. In particular, the communication unit **260** is capable of providing transmission and reception of electronic signals to and from a monitoring unit **270**, such as a handheld computer or PDA that can communicate with the medical device **200** wirelessly or by cable. The communication unit **260** may include hardware, software, firmware, or any combination thereof.

The medical device **200** may also comprise one or more sensor(s) **212** coupled via sensor lead(s) **211** to the medical device **200**. The sensor(s) **212** are capable of receiving signals related to a physiological parameter, such as the patient's heart beat, blood pressure, and/or temperature, and delivering the signals to the medical device **200**. The sensor **212** may also be capable of detecting kinetic signal associated with a patient's movement. The sensor **212**, in one embodiment, may be an accelerometer. The sensor **212**, in another embodiment, may be an inclinometer. In another embodiment, the sensor **212** may be an actigraph. In one embodiment, the sensor(s) **212** may be the same as implanted electrode(s) **126**, **128** (FIG. 1). In other embodiments, the sensor(s) **212** are external structures that may be placed on the patient's skin, such as over the patient's heart or elsewhere on the patient's

torso. The sensor **212**, in one embodiment is a multimodal signal sensor capable of detecting various autonomic and neurologic signals, including kinetic signals associated with the patient's movement.

In one embodiment, the medical device **200** may comprise a autonomic signal module **265** that is capable of collecting autonomic data, e.g., cardiac data comprising fiducial time markers of each of a plurality of heart beats. The autonomic signal module **265** may also process or condition the autonomic data. The autonomic data may be provided by the sensor(s) **212**. The autonomic signal module **265** may be capable of performing any necessary or suitable amplifying, filtering, and performing analog-to-digital (A/D) conversions to prepare the signals for downstream processing. The autonomic data module **265**, in one embodiment, may comprise software module(s) that are capable of performing various interface functions, filtering functions, etc. In another embodiment, the autonomic signal module **265** may comprise hardware circuitry that is capable of performing these functions. In yet another embodiment, the autonomic signal module **265** may comprise hardware, firmware, software and/or any combination thereof. A more detailed illustration of the autonomic signal module **265** is provided in FIG. 3A and accompanying description below.

The autonomic signal module **265** is capable of collecting autonomic data and providing the collected autonomic data to a detection module **285**.

In one embodiment, the medical device **200** may comprise a neurological signal module **275** that is capable of collecting neurologic data, e.g., kinetic signals indicative of the patient's movement. The neurological signal module **275** may also process or condition the neurologic data. The neurologic data may be provided by the sensor(s) **212**. The neurological signal module **275** may be capable of performing any necessary or suitable amplifying, filtering, and performing analog-to-digital (A/D) conversions to prepare the signals for downstream processing. The neurological signal module **275**, in one embodiment, may comprise software module(s) that are capable of performing various interface functions, filtering functions, etc. In another embodiment, the neurological signal module **275** may comprise hardware circuitry that is capable of performing these functions. In yet another embodiment, the neurological signal module **275** may comprise hardware, firmware, software and/or any combination thereof. Further description of the neurologic signal module **275** is provided in FIG. 3B and accompanying description below.

The neurological signal module **275** is capable of collecting autonomic data and providing the collected autonomic data to a detection module **285**.

The detection module **285** is capable of detecting an epileptic event based upon an autonomic signal provided by autonomic signal module **265** and neurological signal module **275**. The detection module **285** can implement one or more algorithms using the autonomic data and neurologic data in any particular order, weighting, etc. The detection module **285** may comprise software module(s) that are capable of performing various interface functions, filtering functions, etc. In another embodiment, the detection module **285** may comprise hardware circuitry that is capable of performing these functions. In yet another embodiment, the detection module **285** may comprise hardware, firmware, software and/or any combination thereof. Further description of the detection module **285** is provided in FIG. 3C and accompanying description below.

In addition to components of the medical device **200** described above, a medical device system may comprise a

storage unit to store an indication of at least one of seizure or an increased risk of a seizure. The storage unit may be the memory 217 of the medical device 200, another storage unit of the medical device 200, or an external database, such as a local database unit 255 or a remote database unit 250. The medical device 200 may communicate the indication via the communications unit 260. Alternatively or in addition to an external database, the medical device 200 may be adapted to communicate the indication to at least one of a patient, a caregiver, or a healthcare provider.

In various embodiments, one or more of the units or modules described above may be located in a monitoring unit 270 or a remote device 292, with communications between that unit or module and a unit or module located in the medical device 200 taking place via communication unit 260. For example, in one embodiment, one or more of the autonomic signal module 265, the neurologic signal module 275, or the detection module 285 may be external to the medical device 200, e.g., in a monitoring unit 270. Locating one or more of the autonomic signal module 265, the neurologic signal module 275, or the detection module 285 outside the medical device 200 may be advantageous if the calculation(s) is/are computationally intensive, in order to reduce energy expenditure and heat generation in the medical device 200 or to expedite calculation.

The monitoring unit 270 may be a device that is capable of transmitting and receiving data to and from the medical device 200. In one embodiment, the monitoring unit 270 is a computer system capable of executing a data-acquisition program. The monitoring unit 270 may be controlled by a healthcare provider, such as a physician, at a base station in, for example, a doctor's office. In alternative embodiments, the monitoring unit 270 may be controlled by a patient in a system providing less interactive communication with the medical device 200 than another monitoring unit 270 controlled by a healthcare provider. Whether controlled by the patient or by a healthcare provider, the monitoring unit 270 may be a computer, preferably a handheld computer or PDA, but may alternatively comprise any other device that is capable of electronic communications and programming, e.g., hand-held computer system, a PC computer system, a laptop computer system, a server, a personal digital assistant (PDA), an Apple-based computer system, a cellular telephone, etc. The monitoring unit 270 may download various parameters and program software into the medical device 200 for programming the operation of the medical device, and may also receive and upload various status conditions and other data from the medical device 200. Communications between the monitoring unit 270 and the communication unit 260 in the medical device 200 may occur via a wireless or other type of communication, represented generally by line 277 in FIG. 2. This may occur using, e.g., wand 155 (FIG. 1) to communicate by RF energy with an implantable signal generator 110. Alternatively, the wand may be omitted in some systems, e.g., systems in which the MD 200 is non-implantable, or implantable systems in which monitoring unit 270 and MD 200 operate in the MICS bandwidths.

In one embodiment, the monitoring unit 270 may comprise a local database unit 255. Optionally or alternatively, the monitoring unit 270 may also be coupled to a database unit 250, which may be separate from monitoring unit 270 (e.g., a centralized database wirelessly linked to a handheld monitoring unit 270). The database unit 250 and/or the local database unit 255 are capable of storing various patient data. These data may comprise patient parameter data acquired from a patient's body, therapy parameter data, seizure severity data, and/or therapeutic efficacy data. The database unit 250 and/or

the local database unit 255 may comprise data for a plurality of patients, and may be organized and stored in a variety of manners, such as in date format, severity of disease format, etc. The database unit 250 and/or the local database unit 255 may be relational databases in one embodiment. A physician may perform various patient management functions (e.g., programming parameters for a responsive therapy and/or setting references for one or more detection parameters) using the monitoring unit 270, which may include obtaining and/or analyzing data from the medical device 200 and/or data from the database unit 250 and/or the local database unit 255. The database unit 250 and/or the local database unit 255 may store various patient data.

One or more of the blocks illustrated in the block diagram of the medical device 200 in FIG. 2 may comprise hardware units, software units, firmware units, or any combination thereof. Additionally, one or more blocks illustrated in FIG. 2 may be combined with other blocks, which may represent circuit hardware units, software algorithms, etc. Additionally, any number of the circuitry or software units associated with the various blocks illustrated in FIG. 2 may be combined into a programmable device, such as a field programmable gate array, an ASIC device, etc.

Turning to FIG. 3A, an autonomic signal module 265 is shown in more detail. The autonomic signal module 265 can comprise a cardiovascular signal unit 312 capable of providing at least one cardiovascular signal. Alternatively or in addition, the autonomic signal module 265 can comprise a respiratory signal unit 314 capable of providing at least one respiratory signal. Alternatively or in addition, the autonomic signal module 265 can comprise a blood parameter signal unit 323 capable of providing at least one blood parameter signal (e.g., blood glucose, blood pH, blood gas, etc). Alternatively or in addition, the autonomic signal module 265 can comprise a temperature signal unit 316 capable of providing at least one temperature signal. Alternatively or in addition, the autonomic signal module 265 can comprise an optic signal unit 318 capable of providing at least one optic signal. Alternatively or in addition, the autonomic signal module 265 can comprise a chemical signal unit 320 capable of providing at least one body chemical signal. Alternatively or in addition, the autonomic signal module 265 can comprise a hormone signal unit 322 capable of providing at least one hormone signal. Alternatively or in addition, the autonomic signal module 265 can comprise one or more other autonomic signal unit(s) 324, such as a skin resistance signal unit.

The autonomic signal module 265 can also comprise an autonomic signal processing unit 330. The autonomic signal processing unit 330 can perform any filtering, noise reduction, amplification, or other appropriate processing of the data received by the signal units 312-324 desired by the person of ordinary skill in the art prior to calculation of the autonomic signal.

The autonomic signal module 265 can also comprise an autonomic signal calculation unit 340. The autonomic signal calculation unit 340 can calculate an autonomic signal from the data passed by the autonomic signal processing unit 330. A calculated autonomic signal herein refers to any signal derivable from the provided signals, with or without processing by the autonomic signal processing unit 330.

For example, the autonomic signal calculation unit 340 may calculate the heart rate, a change in the heart rate, the speed of change in heart rate, blood pressure, heart sounds, heart rhythm, heartbeat morphology at various scales (see, e.g., U.S. Ser. No. 12/884,051, filed Sep. 16, 2010, and U.S. Ser. No. 12/886,419, filed Sep. 20, 2010, which are hereby incorporated herein by reference), or the shape of the deflec-

tion of the thoracic wall as the heart apex beats against it, among others, from cardiovascular data received by cardiovascular signal unit **312**.

For another example, the autonomic signal calculation unit **340** may calculate the respiration (breath) rate, respiration pattern, airflow velocity, respiration amplitude (tidal volume, minute volume), arterial gas concentrations such as end-tidal carbon dioxide, among others, from respiratory data received by respiratory signal unit **314**.

For still another example, the autonomic signal calculation unit **340** may calculate a change in the skin temperature or skin electrical resistance of a part of the patient's face or a change in the core temperature of the patient, from temperature data received by temperature signal unit **316**.

Turning to FIG. 3B, an exemplary embodiment of a neurologic signal module **275** is shown. The neurologic signal module **275** can comprise at least one of a neuro-electrical signal unit **3012** capable of providing at least one neuro-electrical signal; a neuro-chemical signal unit **3014** capable of providing at least one neuro-chemical signal; a neuro-electrochemical signal unit **3016** capable of providing at least one neuro-electrochemical signal; a kinetic signal unit **3018** capable of providing at least one kinetic signal; or a cognitive signal unit **3020** capable of providing at least one cognitive signal. The cognitive signal unit **3020** may be a component of a remote device.

In one embodiment, the cognitive signal unit comprises at least one of a cognitive aptitude determination unit **3020a** capable of processing at least one cognitive aptitude indication; an attention aptitude determination unit **3020b** capable of processing at least one attention aptitude indication; a memory aptitude determination unit **3020c** capable of processing at least one memory indication; a language aptitude determination unit **3020d** capable of processing at least one language indication; a visual/spatial aptitude determination unit **3020e** capable of processing at least one visual/spatial indication; one or more other neurologic factor determination unit(s) **3020g**; or a responsiveness determination unit **3020h**.

The neurologic signal module **275** can also comprise a neurologic signal processing unit **3030**. The neurologic signal processing unit **3030** can perform any filtering, noise reduction, amplification, or other appropriate processing of the data received by the signal units **3012-3020** desired by the person of ordinary skill in the art prior to calculation of the neurologic signal.

The neurologic signal module **275** can also comprise a neurologic signal calculation unit **3040**. The neurologic signal calculation unit **3040** can calculate a neurologic signal from the data passed by the neurologic signal processing unit **3030**. A calculated neurologic signal herein refers to any signal derivable from the provided signals.

For example, the neurologic signal calculation unit **3040** may calculate a brain activity, such as those determinable from signals yielded by an EEG, ECoG, or depth electrodes (i.e., a deep brain electrode), as received by neuro-electrical signal unit **3012**, neuro-chemical signal unit **3014**, and/or neuro-electrochemical signal unit **3016** and, optionally, further processed by neurologic data processing unit **3030**.

A calculated signal regarding brain activity can also be calculated using other neurological signals. For example, spikes in neurons or axons in the brain and spinal cord including central structures and pathways with autonomic control or modulatory capabilities, cranial nerves (e.g., vagus nerve), autonomic ganglia or nerves and peripheral nerves can be sensed and signals provided. Neural imaging or brain imaging signals may be provided, including, for example: Functional Magnetic Resonance Imaging (fMRI), Magnetoen-

cephalography (MEG), Positron Emission Tomography (PET), Event-Related Optical Signal (EROS), and Diffuse Optical Imaging (DOI)). Other imaging techniques such as voltage-sensitive dyes, ultrasound, infra-red, near infra-red and other forms of thermography may also provide signals from which a brain activity can be calculated.

For another example, the neurologic signal calculation unit **3040** may calculate a body kinetic signal, such as the body's (or of a portion thereof such as the head, an arm, or a leg) acceleration; direction; position; smoothness, amplitude, force of movements and number of movements per unit time, and whether there are extraneous or abnormal body oscillations during resting conditions or movement. The signal may be provided by electromyography, a mechanogram, an accelerometer, an actigraph, and/or an inclinometer, as received by kinetic capability determination unit **3018**, and, optionally, further processed by neurologic data processing unit **3030**.

Kinetic signals provide insight into the functional state of the nervous system and are thus classified as a neurologic signal. The ability to perform movements: a) in any direction; b) do it smoothly and with precision so that for example, a target (e.g. putting a key into its hole) may be met in the first attempt or handwriting is legible; c) changing direction to avoid colliding with an object interposed on its path to a target and re-adjusting the trajectory to reach the original target; and d) with adaptive force and discriminations so to be able to pick a penny off a flat surface and also lift heavy objects. The acceleration and velocity speed, direction and smoothness may be quantified using tools such as 3-D accelerometers among others.

Turning to FIG. 3C, a block diagram of detection module **285** is depicted. The detection module **285** comprises a calculated signal receiving module **3110** capable of receiving data indicative of a calculated signal from one or more of the autonomic signal module **265** and the neurologic signal module **275** or a memory **217** storing prior outputs of such a module, and epilepsy event determination module **3120** capable of determining from the received data the occurrence of an epileptic event, e.g., a seizure. The epilepsy event determination module **3120** may implement any appropriate algorithms for determining an epilepsy event from autonomic signals and neurologic signals, e.g., from cardiac data and kinetic data, such as those referred to above.

In the embodiment shown in FIG. 3C, the detection module **285** further comprises an epilepsy event quantification module **3130** capable of quantifying from the received data one or more quantifiable characteristics of an epileptic event, e.g., a seizure. Exemplary quantifiable characteristics include, but are not limited to, event duration, duration of stages of the event (e.g., preictal, ictal, and/or postictal stages), values and/or ranges thereof of one or more body signals (e.g., a peak heart rate, a time series of heart rate, etc.), among others.

In the embodiment shown in FIG. 3C, the detection module **285** also comprises an epilepsy event classification module **3140** capable of classifying an epileptic event, e.g., a seizure, e.g., as a partial seizure, a generalized seizure, or an absence seizure; as a simple partial or complex partial seizure; as a primarily generalized seizure or a secondarily generalized seizure, etc. This module may be also used to classify events as epileptic or non-epileptic (e.g., pseudo-seizures, psychogenic seizures, etc.) Although FIG. 3C shows both an epilepsy event quantification module **3130** and an epilepsy event classification module **3140**, in other embodiments, either or both of modules **3130-3140** may be omitted.

The detection module **285** may send the output of the epilepsy event determination module **3120** to one or more other modules of the medical device **200** and/or one or more

external units. The one or more other modules may then store the output, report the output to the patient, a physician, and/or a caregiver; warn the patient or a caregiver of an epileptic event, etc.

The medical device system of one embodiment of the present invention provides for software module(s) that are capable of acquiring, storing, and processing various forms of data, such as patient data/parameters (e.g., physiological data, side-effects data, heart rate data, breathing rate data, brain-activity parameters, disease progression or regression data, quality of life data, etc.) and therapy parameter data. Therapy parameters may include, but are not limited to, electrical signal parameters (e.g., frequency, pulse width, wave shape, polarity, geometry of electrical fields, on-time, off-time, etc.) that define therapeutic electrical signals delivered by the medical device in response to the detection of the seizure, medication type, dose, or other parameters, and/or any other therapeutic treatment parameter.

In one embodiment, the medical device 200 or an external unit 270 may also be capable of detecting a manual input from the patient. The manual input may include a magnetic signal input, a tap input, a button, dial, or switch input, a touchscreen input, a wireless data input to the medical device 200, etc. The manual input may be used to allow capture of the patient's subjective assessment of his or her epileptic events. For example, the medical device 200 may comprise one or more physical or virtual (e.g., touchscreen-implemented) buttons accessible to the patient's fingers or a caregiver's, through which the patient or caregiver may indicate he or she is having an epileptic event or is not having an epileptic event. Alternatively or in addition, the manual input may be used to gauge the patient's responsiveness.

The above methods may be performed by a computer readable program storage device encoded with instructions that, when executed by a computer, perform the method described herein.

All of the methods and apparatuses disclosed and claimed herein may be made and executed without undue experimentation in light of the present disclosure. While the methods and apparatus of this invention have been described in terms of particular embodiments, it will be apparent to those skilled in the art that variations may be applied to the methods and apparatus and in the steps, or in the sequence of steps, of the method described herein without departing from the concept, spirit, and scope of the invention, as defined by the appended claims. It should be especially apparent that the principles of the invention may be applied to selected cranial nerves other than, or in addition to, the vagus nerve to achieve particular results in treating patients having epilepsy, depression, or other medical conditions.

In certain embodiments, the present invention relates to one or more of the following numbered paragraphs:

1. A medical device (implantable or non-implantable) for detecting, quantifying, and/or classifying an epileptic event based upon an autonomic signal and a neurologic signal of a patient, comprising:

a detection, quantification, and/or classification module(s) for receiving an autonomic signal indicative of the patient's autonomic activity and for receiving a neurologic signal indicative of the patient's neurological activity;

a processing element for determining whether an epileptic event has occurred, a quantifiable characteristic of an epileptic event, and/or a class of an epileptic event, based upon the autonomic signal and the neurologic signal.

2. The implantable medical device of numbered paragraph 1, wherein the autonomic signal is selected from the group

consisting of a cardiac signal, a respiratory signal, a skin resistivity signal, a pupillary signal, a blood signal, and two or more thereof

3. The implantable medical device of numbered paragraph 1, wherein the neurologic signal is selected from the group consisting of a brain signal, a kinetic signal, and two or more thereof

4. The implantable medical device of numbered paragraph 1, wherein the processing element is further capable of determining whether an epileptic event has occurred, quantifying an epileptic event, or classifying an epileptic event by: identifying a putative epileptic event, a quantifiable characteristic of an epileptic event, and/or a class of an epileptic event based on one of the autonomic signal and the neurologic signal; and validating the identifying based on the other of the autonomic signal and the neurologic signal.

101. A method for detecting a generalized tonic-clonic epileptic seizure based upon two or more of a patient's body signals, comprising:

providing at least two body signals selected from the group consisting of a cardiac signal indicative of the patient's heart beats; an accelerometer signal indicative of the patient's movement; an inclinometer signal indicative of the patient's body position; an actigraph signal indicative of the patient's movement, body position, or both; a respiratory signal indicative of the patient's respiration; a skin resistivity signal indicative of the patient's skin resistivity; an blood gas signal indicative of the patient's blood oxygen content, carbon dioxide content, or both; a blood pH signal indicative of the patient's blood pH; an isometric force signal indicative of the patient's muscle activity; a sound signal indicative of the patient's oral utterances or vocalizations; an ocular signal indicative of the patient's eye movement; a responsiveness signal indicative of the patient's responsiveness; an awareness signal indicative of the patient's awareness; an eye activity signal indicative of the patient's eye activity; and a stress marker signal indicative of at least one stress marker of the patient; and

detecting the generalized tonic-clonic epileptic seizure based upon the timewise correlation of two features, one feature being of each of the at least two body signals, wherein:

the feature of the cardiac signal is an increase in the patient's heart rate above an interictal reference value;

the feature of the accelerometer signal is an increase in the patient's movement above an interictal reference value followed by a decrease in the patient's movement below an interictal reference value;

the feature of the inclinometer signal is a change of the patient's body position indicative of either loss of or increase in postural tone, resulting in a fall;

the feature of the actigraph signal is an increase in the patient's movement above an interictal reference value followed by a decrease in the patient's movement below an interictal reference value, or a change of the patient's body position indicative of a change in body posture including but not limited to a fall;

the feature of the respiratory signal is a respiration rate outside an interictal reference value range;

the feature of the skin resistivity signal is a change in the patient's skin resistivity outside an interictal reference value; the feature of the blood gas signal is a decrease in the patient's blood oxygen content below an interictal reference value, an increase in carbon dioxide content above an interictal reference value, or both;

the feature of the blood pH signal is a decrease in the patient's blood pH below an interictal reference value;

the feature of the isometric force signal is an increase in the patient's muscle activity above an interictal reference value; the feature of the sound signal is an increase in the patient's oral utterances or vocalizations indicative of an epileptic cry; the feature of the ocular signal is a forced eye deviation; the feature of the responsiveness signal is a decrease in the patient's responsiveness below an interictal reference value; the feature of the awareness signal is a decrease in the patient's awareness below an interictal reference value; the feature of the eye signal is a change in one or more of blinking rate, blinking amplitude, and inter-blinking interval outside an interictal reference value range; and the feature of the stress marker signal is an increase in at least one stress marker of the patient above an interictal reference value.

102. The method of numbered paragraph 101, further comprising:

indicating the end of the generalized tonic-clonic epileptic seizure when each of the features is outside the value or range of values associated with the ictal state for the respective body signal.

103. The method of numbered paragraph 101, further comprising:

indicating the beginning of a post-ictal period based upon the appearance of at least one post-ictal feature of at least one said body signal, wherein:

the post-ictal feature of the cardiac signal is a decrease in the patient's heart rate below an ictal reference value; the post-ictal feature of the accelerometer signal is a decrease in the patient's movement below an ictal reference value; the post-ictal feature of the respiratory signal is an increase in the patient's respiration rate above an ictal reference value; the post-ictal feature of the responsiveness signal is an increase in the patient's responsiveness above an ictal value and below an inter-ictal reference value; and the post-ictal feature of the awareness signal is an increase in the patient's awareness above an ictal value and below an inter-ictal reference value.

104. The method of numbered paragraph 103, further comprising:

indicating the end of the post-ictal period when each of the post-ictal features is outside the range of values associated with the ictal and post-ictal states.

201. A computer readable program storage device encoded with instructions that, when executed by a computer, performs a method for detecting a partial epileptic seizure based upon two or more of a patient's body signals, comprising:

providing at least two body signals selected from the group consisting of a cardiac signal indicative of the patient's heart beats; an accelerometer signal indicative of the patient's movement; an inclinometer signal indicative of the patient's body position; an actigraph signal indicative of the patient's movement, body position, or both; a respiratory signal indicative of the patient's respiration; a skin resistivity signal indicative of the patient's skin resistivity; an blood gas signal indicative of the patient's blood oxygen content, carbon dioxide content, or both; a blood pH signal indicative of the patient's blood pH; a sound signal indicative of the patient's oral utterances or vocalizations; a responsiveness signal indicative of the patient's responsiveness; an awareness signal indicative of the patient's awareness; an eye activity signal indicative of at least one eye activity of a patient; and a stress marker signal indicative of at least one stress marker of the patient; and

detecting the partial epileptic seizure based upon the timewise correlation of two features, one feature being of each of the at least two body signals, wherein:

the feature of the cardiac signal is a heart rate outside an interictal reference value range;

the feature of the accelerometer signal is a movement outside an interictal reference value range;

5 the feature of the actigraph signal is a movement outside an interictal reference value range;

the feature of the respiratory signal is a respiration rate outside an interictal reference value range;

10 the feature of the skin resistivity signal is a skin resistivity outside an interictal reference value;

the feature of the blood gas signal is a blood oxygen content outside an interictal reference value range, a carbon dioxide content outside an interictal reference value range, or both;

15 the feature of the blood pH signal is a blood pH outside an interictal reference value range;

the feature of the sound signal is an increase or a decrease in the patient's oral utterances or vocalizations above an interictal reference value;

20 the feature of the eye signal is a change in one or more of blinking rate, blinking amplitude, and inter-blinking interval outside an interictal reference value range;

and the feature of the stress marker signal is a concentration of at least one stress marker of the patient above an interictal reference value.

202. The computer readable program storage device encoded with instructions that, when executed by a computer, perform the method of numbered paragraph 201, wherein the method further comprises:

30 classifying the partial epileptic seizure as a complex partial seizure if a feature of the signal timewise correlated with the at least two body signals and/or a feature of the awareness signal timewise correlated with the at least two body signals is a decrease in the patient's responsiveness below its reference value and/or awareness below its reference value, and as a simple partial seizure if there is no decrease in the patient's responsiveness below its reference value and no decrease in the patient's awareness below its reference value or, if there is a decrease in the patient's responsiveness but awareness remains preserved.

203. The computer readable program storage device encoded with instructions that, when executed by a computer, perform the method of numbered paragraph 201, wherein the method further comprising:

indicating the end of the partial epileptic seizure when each of the features of the respective body signals is outside the range of values associated with the ictal state for that body signal.

204. The computer readable program storage device encoded with instructions that, when executed by a computer, perform the method of numbered paragraph 201, wherein the method further comprising:

indicating the beginning of a post-ictal period when each of the respective body signals is outside the range of values associated with the ictal and inter-ictal states for that body signal, wherein:

the cardiac signal outside the range of values associated with the ictal state;

the post-ictal feature of the accelerometer signal is a change in the patient's movement outside the ictal range of values;

60 the post-ictal feature of the respiratory signal is a change in the patient's respiration to a value outside an ictal reference value;

the post-ictal feature of the responsiveness signal is an increase in the patient's responsiveness above an ictal reference value but remaining below and inter-ictal reference value; and

the post-ictal feature of the awareness signal is an increase in the patient's awareness above an ictal reference value but remaining below an inter-ictal reference value.

205. The computer readable program storage device encoded with instructions that, when executed by a computer, perform the method of numbered paragraph 204, wherein the method further comprises:

indicating the end of the post-ictal period when each of the features is absent from its respective body signal.

301. A medical device system for detecting an epileptic event based upon multimodal signals, comprising:

a first sensor for detecting a first modal data and a second sensor for detecting a second modal data relating to a patient's body, the first modal data comprising a neurologic signal and the second modal data comprising an autonomic signal of the patient's body; and

an implantable medical device (IMD) operatively coupled to the first sensor and the second sensor; the IMD comprising:

a neurologic signal module for receiving the neurologic signal;

an autonomic signal module for receiving the autonomic signal; and

a processing element for determining whether an epileptic event has occurred based upon the first and second modal data.

401. A method for detecting, quantifying, and/or classifying an epileptic event based upon two or more of a patient's body signals, comprising:

providing at least one body signal selected from the group consisting of a cardiac signal indicative of the patient's heart beats; an accelerometer signal indicative of the patient's movement; an inclinometer signal indicative of the patient's body position; an actigraph signal indicative of the patient's movement, body position, or both; a respiratory signal indicative of the patient's respiration; a skin resistivity signal indicative of the patient's skin resistivity; an blood gas signal indicative of the patient's blood oxygen content, carbon dioxide content, or both; a blood pH signal indicative of the patient's blood pH; an isometric force signal indicative of the patient's muscle activity; a sound signal indicative of the patient's oral utterances or vocalizations; an ocular signal indicative of the patient's eye movement; a responsiveness signal indicative of the patient's responsiveness; an awareness signal indicative of the patient's awareness; and a stress marker signal indicative of at least one stress marker of the patient;

detecting a transition from a preictal time period to an ictal time period using at least a first body signal;

detecting a transition from a preictal time period to an ictal time period using at least a second body signal;

detecting a transition from an ictal time period to a postictal time period using at least a third body signal; and

detecting a transition from a postictal time period to an inter-ictal time period using at least a fourth body signal.

402. The method of numbered paragraph 401, wherein the first body signal, the second body signal, the third, body signal and the fourth body signal are selected from at least two provided body signals.

The particular embodiments disclosed above are illustrative only as the invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown other than as described in the claims below. It is, therefore, evident that the particular embodiments disclosed above may be altered or modified and all

such variations are considered within the scope and spirit of the invention. Accordingly, the protection sought herein is as set forth in the claims below.

What is claimed:

1. A method for detecting an epileptic event based upon a patient's cardiac signal and kinetic activity, comprising:

providing a cardiac signal indicative of the patient's heart activity;

determining at least one cardiac index from the cardiac signal, wherein said at least one cardiac index is selected from a heart rate and at least one EKG morphology feature;

providing a kinetic signal indicative of body movement of the patient;

detecting an epileptic event based on a change in the at least one cardiac index selected from:

an increase in the patient's heart rate;

a decrease in the patient's heart rate; or

a change in said at least one EKG morphology feature; and

performing a further action based on said kinetic signal, wherein said further action is selected from

confirming the detecting of the epileptic event; or

not confirming the detecting of the epileptic event.

2. The method of claim 1 further comprising: determining at least one kinetic index selected from

a body posture,

a body position,

a fall,

a parameter derived from an accelerometer signal selected from a movement, a frequency per unit time, a time interval between movements, a movement direction in at least one plane, an acceleration, a velocity, a force, or a change in one or more of the foregoing, and wherein performing said further action is based on the at least one kinetic index.

3. The method of claim 1 further comprising determining a kinetic index selected from a cessation of movement or an increase in the patient's heart rate.

4. The method of claim 2 wherein performing said further action based on said kinetic signal is based upon the temporal relationship between the change in the at least one cardiac index and the kinetic signal.

5. The method of claim 1 further comprising classifying said epileptic event based upon at least one cardiac index and at least one kinetic index.

6. The method of claim 1, further comprising classifying said epileptic event based upon at least one of the patient's heart rate, heart rhythm, EKG morphology, EKG wave intervals, an accelerometer signal, an inclinometer signal, a respiratory signal, a skin signal, a blood gases signal, a blood pH, an force, vocal sounds, an EMG signal, an oculogram signal, an EEG signal, an ECoG signal, a responsiveness of the patient, an awareness of the patient, or a stress marker.

7. The method of claim 6 wherein classifying said event comprises

classifying the event as one or more of:

an unconfirmed seizure;

a confirmed seizure;

a non-epileptic seizure;

a primarily generalized tonic-clonic seizure,

a secondarily generalized tonic-clonic seizure;

an absence seizure;

a tonic seizure;

an atonic seizure

a partial seizure;

a simple partial seizure;

a complex partial seizure;
a simple partial seizure with secondary generalization; or
a complex partial seizure with secondary generalization.

8. The method of claim 1, further comprising providing, following said confirming the detecting of the epileptic event, at least one of a responsiveness signal indicative of the patient's responsiveness and an awareness signal indicative of the patient's awareness, and classifying the epileptic event based upon the at least one of the responsiveness signal and the awareness signal.

9. A method for detecting an epileptic event based upon a patient's cardiac signal and kinetic activity, comprising:

providing a kinetic signal indicative of body movement of the patient;

determining at least one kinetic index from said kinetic signal, wherein said at least one kinetic index is selected from a body posture, a body position, a fall, a parameter derived from an accelerometer signal selected from a movement, a frequency per unit time, a time interval between movements, a movement direction in at least one plane, an acceleration, a velocity, a force, or a change in one or more of the foregoing;

providing a cardiac signal indicative of the patient's heart activity;

detecting an epileptic event based on said at least one kinetic index; and

performing a further action based on said cardiac signal, wherein said further action is selected from confirming the detecting of the epileptic event; or not confirming the detecting of the epileptic event.

10. The method of claim 9 further comprising: determining at least one cardiac index selected from a heart rate, an EKG morphology feature, an EKG rhythm feature, or an EKG wave interval feature,

and wherein performing said further action is based on the at least one cardiac index.

11. The method of claim 10, further comprising classifying said epileptic event based upon at least one of a cardiac index, a kinetic index, a respiratory index, a skin index, a blood gases signal, a blood pH, a force index, vocal sounds, ocular activity, an EEG signal, an ECoG signal, an EMG signal, a responsiveness of the patient, an awareness of the patient, or a stress marker.

12. The method of claim 1 wherein classifying said event comprises classifying the event as one or more of:

an unconfirmed seizure;
a confirmed seizure;
a non-epileptic seizure;
a primarily generalized tonic-clonic seizure,
a secondarily generalized tonic-clonic seizure;
an absence seizure;
a tonic seizure;
an atonic seizure
a partial seizure;
a simple partial seizure;
a complex partial seizure;
a simple partial seizure with secondary generalization; or
a complex partial seizure with secondary generalization.

13. The method of claim 9, further comprising providing, following said confirming the detecting of the epileptic event, at least one of a responsiveness signal indicative of the patient's responsiveness or an awareness signal indicative of the patient's awareness, and classifying the epileptic event based upon the at least one of the responsiveness signal or the awareness signal.

14. A method for detecting an epileptic event based upon a patient's cardiac signal and kinetic activity, comprising:

providing a cardiac signal indicative of the patient's heart activity;

determining at least one cardiac index from the cardiac signal, wherein said at least one cardiac index is selected from a heart rate, an EKG morphology feature, an EKG rhythm feature, or an EKG wave interval feature;

characterizing the at least one cardiac index as either indicative of an epileptic event or not indicative of an epileptic event;

providing a kinetic signal indicative of body movement and type of body movement of the patient;

characterizing the kinetic signal as either indicative of an epileptic event or not indicative of an epileptic event; and detecting an epileptic event only if both of the heart rate and the kinetic signal are indicative of an epileptic event.

15. The method of claim 14 further comprising performing a further action in response to detecting an epileptic event, wherein said further action is selected from providing a therapy to the patient, providing a warning to one of a patient or a caregiver, or logging data relating to the epileptic event.

16. The method of claim 14 further comprising classifying said epileptic event based upon at least one cardiac index and at least one kinetic index.

17. The method of claim 14 wherein classifying said event comprises classifying the event as one or more of:

an unconfirmed seizure;
a confirmed seizure;
a non-epileptic seizure;
a primarily generalized tonic-clonic seizure,
a secondarily generalized tonic-clonic seizure;
an absence seizure;
a tonic seizure;
an atonic seizure
a partial seizure;
a simple partial seizure;
a complex partial seizure;
a simple partial seizure with secondary generalization;
a complex partial seizure with secondary generalization.

18. The method of claim 14, wherein the cardiac signal is provided by an electrocardiogram (EKG), and the kinetic signal is provided by an accelerometer, an inclinometer, an actigraph, an EMG, a mechanogram or two or more thereof.

19. The method of claim 14, further comprising providing an awareness signal indicative of the patient's awareness following said detecting, and characterizing the epileptic event based upon the awareness signal.

20. A medical device system for detecting an epileptic event based upon multimodal signals, comprising:

a first sensor for detecting a first modal data and a second sensor for detecting a second modal data relating to a patient's body, the first modal data comprising a kinetic signal and the second modal data comprising a cardiac signal of the patient's body; and

a medical device (MD) coupled to the patient's body and operatively coupled to the first sensor and the second sensor; the MD comprising:

a kinetic signal module for receiving the kinetic signal;
a cardiac signal module for receiving the cardiac signal;
a detection module for determining whether an epileptic event has occurred based on:

1) detecting an epileptic event using one of said kinetic signal module and said cardiac signal module, and

41

2) confirming or not confirming said epileptic event using the other of said kinetic signal module and said cardiac signal module.

21. The medical device system of claim **20** further comprising an output module for providing a signal indicating at least one of no seizure detection, a possible seizure detection, or a confirmed seizure detection.

* * * * *

42

专利名称(译)	使用多模态数据检测，量化和/或分类癫痫发作		
公开(公告)号	US8888702	公开(公告)日	2014-11-18
申请号	US13/692738	申请日	2012-12-03
[标]申请(专利权)人(译)	FLINT HILLS SCI L LC		
当前申请(专利权)人(译)	FLINT HILLS科技有限责任公司		
[标]发明人	OSORIO IVAN		
发明人	OSORIO, IVAN		
IPC分类号	A61N1/36 A61B5/0476 A61B5/145 A61B5/11 A61B5/00 A61N1/365 A61B5/0245 A61B5/0205		
CPC分类号	A61B5/0476 A61B5/7282 A61B5/14539 A61B5/0205 A61B5/0245 A61B5/686 A61B5/02055 A61B5/11 A61N1/36585 A61N1/36064 A61B5/7264 A61N1/36135 A61B5/4094 A61B5/14542 A61B7/003 A61B5/0488 A61B5/02405 A61B3/113 A61B5/0472 A61B5/08 A61B5/165 A61B5/1117 A61B5/0468 A61B5/0531 G16H50/20		
其他公开文献	US20130096441A1		
外部链接	Espacenet USPTO		

摘要(译)

用于检测癫痫事件的方法, 系统和设备, 例如, 使用医疗设备在患者中发作。通过提供指示患者自主活动的自主信号来执行确定; 提供指示患者神经活动的神经信号; 并基于自主信号和神经信号检测癫痫事件。

